<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="cf" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">cf</book-part-id>
      <title-group>
        <title>Cystic Fibrosis and Congenital Absence of the Vas Deferens</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ong</surname>
            <given-names>Thida</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Division of Pulmonary and Sleep Medicine<break/>Seattle Children&#x02019;s Hospital<break/>University of Washington School of Medicine<break/>Seattle, Washington</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Marshall</surname>
            <given-names>Susan G</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Division of Pulmonary and Sleep Medicine<break/>Seattle Children&#x02019;s Hospital<break/>University of Washington School of Medicine<break/>Seattle, Washington</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Karczeski</surname>
            <given-names>Barbara A</given-names>
          </name>
          <degrees>MS, CGC</degrees>
          <aff>DNA Diagnostic Laboratory<break/>Johns Hopkins University School of Medicine<break/>Baltimore, Maryland</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sternen</surname>
            <given-names>Darci L</given-names>
          </name>
          <degrees>MS, LGC</degrees>
          <aff>Department of Laboratories and Pediatric Laboratory Utilization Guidance Services<break/>Seattle Children&#x02019;s Hospital<break/>Seattle, Washington</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cheng</surname>
            <given-names>Edith</given-names>
          </name>
          <degrees>MS, MD</degrees>
          <aff>Department of Obstetrics and Gynecology<break/>University of Washington School of Medicine <break/>Seattle, Washington</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cutting</surname>
            <given-names>Garry R</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Institute of Genetic Medicine<break/>Departments of Pediatrics and Medicine<break/>Johns Hopkins University School of Medicine <break/>Baltimore, Maryland</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>26</day>
          <month>3</month>
          <year>2001</year>
        </date>
        <date date-type="updated">
          <day>2</day>
          <month>2</month>
          <year>2017</year>
        </date>
        <date date-type="revised">
          <day>24</day>
          <month>8</month>
          <year>2005</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="creatine" document-type="chapter">Creatine Deficiency Syndromes</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="ctns" document-type="chapter">Cystinosis</related-object>
      <abstract id="cf.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Cystic fibrosis (CF) is a multisystem disease affecting epithelia of the respiratory tract, exocrine pancreas, intestine, hepatobiliary system, and exocrine sweat glands. Morbidities include progressive obstructive lung disease with bronchiectasis, frequent hospitalizations for pulmonary disease, pancreatic insufficiency and malnutrition, recurrent sinusitis and bronchitis, and male infertility. Pulmonary disease is the major cause of morbidity and mortality in CF. Meconium ileus occurs at birth in 15%-20% of newborns with CF. More than 95% of males with CF are infertile.</p>
          <p>Congenital absence of the vas deferens (CAVD) is generally identified during evaluation of infertility or as an incidental finding at the time of a surgical procedure. Hypoplasia or aplasia of the vas deferens and seminal vesicles may occur either bilaterally or unilaterally. Testicular development and function and spermatogenesis are usually normal.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of CF is established in a proband with one or more characteristic phenotypic features and evidence of an abnormality in cystic fibrosis transmembrane conductance regulator (CFTR) function (e.g., 2 elevated sweat chloride values, biallelic <italic toggle="yes">CFTR</italic> pathogenic variants, or transepithelial nasal potential difference measurement characteristic of CF). The diagnosis of CF is established in an infant with elevated trypsinogen on newborn screening and identification of biallelic <italic toggle="yes">CFTR</italic> pathogenic variants or an elevated sweat chloride.</p>
          <p>The diagnosis of CAVD is established in a male with azoospermia and absence of the vas deferens on palpation or identification of biallelic CAVD-causing <italic toggle="yes">CFTR</italic> pathogenic variants.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Treatment of respiratory complications using inhaled dornase alfa, inhaled hypertonic saline, antibiotics, anti-inflammatory agents, ivacaftor, ivacaftor/lumacaftor combined therapy, lung or heart/lung transplant; topical steroids, antibiotics and/or surgical intervention for nasal/sinus symptoms; treatment of exocrine pancreatic insufficiency using oral pancreatic enzyme replacement, special infant formulas, supplemental nutrition, fat-soluble vitamin supplements and zinc; management of CF-related diabetes mellitus (CFRD) by an endocrinologist; surgical management for meconium ileus; oral ursodiol for biliary sludging/obstruction, liver transplant when indicated; assisted reproductive technologies (ART) for male infertility.</p>
          <p><italic toggle="yes">Prevention of primary complications:</italic> Airway clearance techniques, dornase alpha, hypertonic saline, antibiotics to prevent chronic airway infection, immunizations including anti-RSV monoclonal antibody; physical activity to maintain bone health and improve airway clearance; nutritional support for pancreatic insufficiency; extra salt and water in hot, dry climates.</p>
          <p><italic toggle="yes">Surveillance:</italic> Frequent visits to CF care providers to monitor for changes in symptoms and physical examination; cultures of respiratory tract secretions at least four times yearly; pulmonary function studies, chest radiographic examination, annual electrolytes, fat-soluble vitamin levels and IgE levels; bronchoscopy and chest CT examination when indicated; monitor weight gain and caloric intake in infants until age six months; fecal elastase when indicated; annual oral glucose tolerance test in individuals older than age ten years; evaluation of bone mineral density starting in adolescence; annual liver function tests and liver ultrasound to monitor progression of liver disease.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Respiratory irritants; individuals with respiratory infections; dehydration.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Molecular genetic testing of at-risk sibs if the pathogenic variants in the family are known or sweat chloride testing of at-risk sibs if the pathogenic variants in the family are not known, to identify as early as possible those who should be referred to a cystic fibrosis center for initiation of treatment and preventive measures.</p>
          <p><italic toggle="yes">Therapies under investigation:</italic> Prophylactic ursodiol therapy; CF corrector VX-661; inhaled dry powder mannitol; <italic toggle="yes">CFTR</italic> gene therapy.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>CF and CAVD are inherited in an autosomal recessive manner. At conception, each sib of an affected individual with CF and brothers of a male with CAVD have a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the <italic toggle="yes">CFTR</italic> pathogenic variants in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="cf.Diagnosis">
        <title>Diagnosis</title>
        <sec id="cf.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p><bold>Cystic fibrosis (CF) should be suspected</bold> in individuals with the following features:</p>
          <list list-type="bullet">
            <list-item>
              <p>Chronic sinopulmonary disease including chronic cough and sputum production, chronic wheeze and air trapping, obstructive lung disease on pulmonary function tests, persistent colonization with pathogens commonly found in individuals with CF, persistent chest radiograph abnormalities, nasal polyps, chronic pan sinusitis, and digital clubbing</p>
            </list-item>
            <list-item>
              <p>Gastrointestinal/nutritional abnormalities such as meconium ileus, rectal prolapse, malabsorption/pancreatic insufficiency, steatorrhea, distal intestinal obstructive syndrome, recurrent acute pancreatitis, chronic pancreatitis, prolonged neonatal jaundice, chronic hepatic disease manifested by clinical or histologica evidence of focal biliary cirrhosis or multilobular cirrhosis, failure to thrive (protein-calorie malnutrition), hypoproteinemia and edema, complications secondary to fat-soluble vitamin deficiencies</p>
            </list-item>
            <list-item>
              <p>Obstructive azoospermia</p>
            </list-item>
            <list-item>
              <p>Salt-loss syndromes including acute salt depletion, chronic metabolic alkalosis, and hyponatremic hypochloremic dehydration</p>
            </list-item>
            <list-item>
              <p>In infants: elevated immunoreactive trypsinogen (IRT) on newborn screening</p>
            </list-item>
          </list>
          <p><bold>Congenital absence of the vas deferens (CAVD) should be suspected</bold> in males with the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Severe oligospermia or azoospermia</p>
            </list-item>
            <list-item>
              <p>A low volume of ejaculated semen with a specific chemical profile (low pH, elevated citric acid concentration, elevated acid phosphatase concentration, low fructose concentration, and failure to coagulate)</p>
            </list-item>
            <list-item>
              <p>Evidence of abnormalities of seminal vesicles or vas deferens on rectal ultrasound examination</p>
            </list-item>
          </list>
        </sec>
        <sec id="cf.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p><bold>The diagnosis of CF</bold>
<bold>is established</bold> in a proband with the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>One or more characteristic phenotypic features of CF and evidence of an abnormality in cystic fibrosis transmembrane conductance regulator (CFTR) function based on ONE of the following:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Two abnormal quantitative pilocarpine iontophoresis sweat chloride values (&#x0003e;60 mEq/L in infants age &#x0003e; 6 months). Click <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="cf-dx_tests.pdf" content-type="local-data">here</inline-supplementary-material> (pdf) for more specific information on this test.</p>
                </list-item>
                <list-item>
                  <p>Identification of biallelic pathogenic or likely pathogenic variants in <italic toggle="yes">CFTR</italic> (see <xref ref-type="table" rid="cf.T.molecular_genetic_testing_used_in_c">Table 1</xref>)</p>
                </list-item>
                <list-item>
                  <p>Transepithelial nasal potential difference measurements characteristic of CF. Click <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="cf-dx_tests.pdf" content-type="local-data">here</inline-supplementary-material> (pdf) for more specific information on this test.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>In an infant: elevated trypsinogen on newborn screening immunoreactive trypsinogen (IRT) assay AND</p>
              <list list-type="bullet">
                <list-item>
                  <p>Identification of biallelic CF-causing pathogenic variants in <italic toggle="yes">CFTR</italic></p>
                  <p>OR</p>
                </list-item>
                <list-item>
                  <p>An abnormal sweat chloride value &#x02265;60 mEq/L (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.acmg.net/StaticContent/ACT/CF.pdf">ACMG Newborn Screening ACT Sheet</ext-link>)</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>The diagnosis of CAVD is established</bold> in a male with the following features:</p>
          <list list-type="bullet">
            <list-item>
              <p>Azoospermia</p>
              <p>AND</p>
            </list-item>
            <list-item>
              <p>Absence of the vas deferens on palpation (rarely, a thin fibrous cord representing a rudimentary vas deferens may be present)</p>
              <p>OR</p>
            </list-item>
            <list-item>
              <p>Identification of biallelic CAVD-causing <italic toggle="yes">CFTR</italic> pathogenic variants (establishes the diagnosis if clinical features are inconclusive; see <xref ref-type="table" rid="cf.T.molecular_genetic_testing_used_in_c">Table 1</xref>)</p>
            </list-item>
          </list>
          <p>Molecular genetic testing approaches include <bold>single-gene testing</bold> and use of a <bold>multi-gene panel</bold>.</p>
          <p>
            <bold>Single-gene testing</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Targeted analysis for <italic toggle="yes">CFTR</italic> pathogenic variants can be performed first.</p>
              <p>Note: The American College of Medical Genetics recommended panel includes the 23 pathogenic variants listed in <xref ref-type="table" rid="cf.T.recommended_panel_of_pathogenic_var">Table 6</xref> and has a detection rate of 97% in Ashkenazi Jewish, 88.3% in non-Hispanic whites, 69% in African Americans, and 57% in Hispanic Americans; detection rate in Asian Americans is unknown [<xref ref-type="bibr" rid="cf.REF.grody.2001">Grody et al 2001</xref>, <xref ref-type="bibr" rid="cf.REF.palomaki.2002.90">Palomaki et al 2002</xref>, <xref ref-type="bibr" rid="cf.REF.watson.2004.387">Watson et al 2004</xref>].</p>
              <p>Note: A panel that includes more than 129 pathogenic variants would detect approximately 96% of pathogenic variants in affected individuals (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cftr2.org">www.cftr2.org</ext-link>) [<xref ref-type="bibr" rid="cf.REF.sosnay.2013.1160">Sosnay et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>Sequence analysis of <italic toggle="yes">CFTR</italic> &#x02013; followed by gene-targeted deletion/duplication analysis &#x02013; is performed if only one or no pathogenic variant is found.</p>
              <p>Note: Sequence analysis of <italic toggle="yes">CFTR</italic>, followed by gene-targeted deletion/duplication analysis, is the initial diagnostic test for:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Individuals of an ethnicity for which the sensitivity of targeted analysis is low;</p>
                </list-item>
                <list-item>
                  <p>Prenatal testing in a high-risk fetus;</p>
                </list-item>
                <list-item>
                  <p>Prenatal testing in a low-risk fetus with echogenic bowel identified on prenatal ultrasound examination;</p>
                </list-item>
                <list-item>
                  <p>An infant with an elevated IRT assay on newborn screening and a sweat chloride of 30-59 mEq/L (intermediate result);</p>
                </list-item>
                <list-item>
                  <p>A symptomatic infant (e.g., infant with meconium ileus) who is too young to produce adequate volumes of sweat.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">CFTR</italic> and other genes of interest (see <xref ref-type="sec" rid="cf.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Notes: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
          <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
          <table-wrap id="cf.T.molecular_genetic_testing_used_in_c" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Cystic Fibrosis (CF) and Congenital Absence of the Vas Deferens (CAVD)</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_2">Test Method</th>
                  <th id="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
                <tr>
                  <th headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_3" id="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">CF</th>
                  <th headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_3" id="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">CAVD</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">CFTR</italic>
                  </td>
                  <td headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_3 hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">97%-98%</td>
                  <td headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_3 hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">79%&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_1_3 hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_2_1 hd_h_cf.T.molecular_genetic_testing_used_in_c_1_1_2_2" valign="middle" colspan="2" align="left" rowspan="1">&#x02264;2%-3%</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="cf.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="cf" object-id="cf.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="cf.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="cf.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="cf.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="cf.TF.1.4">
                <label>4. </label>
                <p>79% of men had at least one pathogenic variant identified, 46% had both <italic toggle="yes">CFTR</italic> pathogenic variants identified; sensitivity varied by ethnicity [<xref ref-type="bibr" rid="cf.REF.yu.2012.25">Yu et al 2012</xref>].</p>
              </fn>
              <fn id="cf.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="cf.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="cf.Clinical_Description">
          <title>Clinical Description</title>
          <p><bold>Cystic fibrosis (CF)</bold> affects the epithelia in several organs resulting in a complex, multisystem disease that involves the respiratory tract, exocrine pancreas, intestine, hepatobiliary system, male genital tract, and exocrine sweat glands. Morbidities include progressive obstructive lung disease with bronchiectasis, frequent hospitalizations for pulmonary disease, pancreatic insufficiency and malnutrition, recurrent sinusitis and bronchitis, and male infertility. The overall median predicted survival is estimated at 40.7 years (95% confidence intervals, 37.7- 44.1 yrs) [CFF <xref ref-type="bibr" rid="cf.REF.patient_registry.2013">Patient Registry 2013</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Respiratory.</bold> Pulmonary disease remains the major cause of morbidity and mortality in CF. Early manifestations are chronic cough, intermittent sputum production, and exertional dyspnea. Bronchiectasis is now known to develop early, detectable in infants as young as age ten weeks, and is persistent and progressive [<xref ref-type="bibr" rid="cf.REF.sly.2013.1963">Sly et al 2013</xref>]. Failure of lung defenses leads to bacterial endobronchitis (most commonly <italic toggle="yes">Staphylococcus aureus</italic> and <italic toggle="yes">Pseudomonas aeruginosa</italic>) with resulting airway obstruction and intense neutrophilic inflammation. Progression of lung disease results in chronic endobronchitis and structural injury to the airways. End-stage lung disease is characterized by extensive damage to the airways (cysts/abscesses) and accompanying fibrosis of lung parenchyma adjacent to airways.</p>
              <p>Other respiratory causes of morbidity include recurrent sinusitis and nasal polyposis.</p>
            </list-item>
            <list-item>
              <p><bold>Exocrine pancreatic insufficiency</bold> with malabsorption occurs in the great majority of individuals with CF, although median body mass index percentiles have steadily increased [CFF <xref ref-type="bibr" rid="cf.REF.patient_registry.2013">Patient Registry 2013</xref>]. Pancreatic insufficiency is caused by inspissation of secretions within the pancreatic ducts and ultimately interstitial fibrosis. The clinical manifestations are steatorrhea and poor growth related to fat malabsorption. Acute or chronic recurrent pancreatitis can be a presenting manifestation of CF, and is much more common among those with pancreatic sufficiency (10% prevalence) than those with pancreatic insufficiency (0.5% prevalence) [<xref ref-type="bibr" rid="cf.REF.de_boeck.2005.e463">De Boeck et al 2005</xref>]. Hemolytic anemia, defective coagulation, or skin rashes related to deficiencies of fat-soluble vitamins and zinc may occasionally be seen.</p>
              <p>Cystic fibrosis-related diabetes (CFRD) can occur at any age, but prevalence increases with age, estimated in 20% of adolescents and 40%-50% of adults [<xref ref-type="bibr" rid="cf.REF.moran.2009.1626">Moran et al 2009</xref>, <xref ref-type="bibr" rid="cf.REF.moran.2014.65">Moran et al 2014</xref>]. CFRD is distinctive from type 1 and type 2 diabetes and requires its own approach to both diagnosis and management [<xref ref-type="bibr" rid="cf.REF.moran.2014.65">Moran et al 2014</xref>]. Glucose metabolism in CFRD is impaired by a loss of total islet cells leading to an absence of insulin and glucagon, and fluctuating insulin resistance occurs from chronic and acute inflammation. CFRD is diagnosed if the fasting glucose level is &#x02265;126 mg/dL (7.0 mmol/L) or the two-hour oral glucose tolerance test glucose level is &#x02265;200 mg/dL (11.1 mmol/L). CFRD can be diagnosed during a pulmonary exacerbation if fasting glucose levels of &#x02265;126 mg/dL (7.0 mmol/L) or the two-hour post prandial levels of &#x02265;200 mg/dL (11.1 mmol/L) persist for 48 hours [<xref ref-type="bibr" rid="cf.REF.moran.2010.2697">Moran et al 2010</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Gastrointestinal.</bold> Meconium ileus occurs in 15%-20% of newborns diagnosed with CF.</p>
            </list-item>
            <list-item>
              <p><bold>Liver disease</bold> typically presents by age ten years and is defined as the presence of at least two of the following: hepatomegaly, elevated serum hepatic enzyme levels, and/or liver ultrasound abnormalities other than hepatomegaly [<xref ref-type="bibr" rid="cf.REF.leeuwen.2014.69">Leeuwen et al 2014</xref>]. Liver disease is reported in approximately 10% of individuals [CFF <xref ref-type="bibr" rid="cf.REF.patient_registry.2013">Patient Registry 2013</xref>]. Approximately 5%-10% develop clinically significant liver disease with multi-lobar cirrhosis and portal hypertension [<xref ref-type="bibr" rid="cf.REF.debray.2011.s29">Debray et al 2011</xref>]. Progression is variable. Individuals with CF may develop focal biliary cirrhosis from progressive portal fibrosis and biliary obstruction. Complications include variceal bleeding, ascites, hypersplenism, hepatic encephalopathy, and rarely liver synthetic failure. Liver disease is the cause of mortality in 2.9% of individuals with CF [CFF <xref ref-type="bibr" rid="cf.REF.patient_registry.2013">Patient Registry 2013</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Fertility.</bold> More than 95% of males with CF are infertile as a result of azoospermia caused by altered vas deferens, which may be absent, atrophic, or fibrotic.</p>
              <p>Women with CF are fertile, although a few females have abnormal cervical mucus that may contribute to infertility. Others with severe illness and reduced body mass index may be anovulatory. The rate of live births among females with CF age 14-45 years is 1.6 per 100 [CFF <xref ref-type="bibr" rid="cf.REF.patient_registry.2011">Patient Registry 2011</xref>].</p>
            </list-item>
          </list>
          <p><bold>Congenital absence of the vas deferens (CAVD)</bold> is generally identified during evaluation of infertility or as an incidental finding at the time of a surgical procedure, such as orchidopexy. CAVD accounts for 1.2%-1.7% of male infertility. Hypoplasia or aplasia of the vas deferens and seminal vesicles may occur either bilaterally or unilaterally. Testicular development and function and spermatogenesis are usually normal.</p>
        </sec>
        <sec id="cf.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cftr2.org/">Clinical and Functional Translation of CFTR</ext-link> website provides information about <italic toggle="yes">CFTR</italic> pathogenic variants including sweat chloride, lung function, pancreatic status, and pseudomonas infection rates in individuals with specific pathogenic variants.</p>
          <p><bold>Cystic fibrosis.</bold> The best correlation between genotype and phenotype is seen in the context of pancreatic function. The most common pathogenic variants have been classified as pancreatic sufficient (PS) or pancreatic insufficient. Individuals with pancreatic sufficiency usually have either one or two PS alleles, indicating that PS alleles are dominant with respect to pancreatic phenotype.</p>
          <p>The severity of pulmonary disease among individuals with identical genotypes varies widely. Limited genotype-phenotype correlations include:</p>
          <p>Compound heterozygotes for p.Phe508del/p.Ala455Glu have better pulmonary function than individuals who are homozygous for p.Phe508del [<xref ref-type="bibr" rid="cf.REF.de_braekeleer.1997.208">De Braekeleer et al 1997</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>The severity of lung disease in individuals heterozygous or homozygous for p.Arg117His depends on the presence of a variation in the poly T tract of intron 9, c.1210-12T[5_9] [<xref ref-type="bibr" rid="cf.REF.massie.2001.1195">Massie et al 2001</xref>]. Individuals with a CF-causing variant plus the 5T variant <italic toggle="yes">in cis</italic> with p.Arg117His usually develop the lung disease of CF, but those individuals with p.Arg117His and the 7T variant or the 9T variant have a highly variable phenotype that can range from no symptoms to mild lung disease [<xref ref-type="bibr" rid="cf.REF.kiesewetter.1993.274">Kiesewetter et al 1993</xref>, <xref ref-type="bibr" rid="cf.REF.chmiel.1999.823">Chmiel et al 1999</xref>].</p>
            </list-item>
            <list-item>
              <p>Because p.Ala455Glu and p.Arg117His are associated with pancreatic sufficiency, the less severe lung disease seen in individuals with these pathogenic variants could be the consequence of better nutritional status.</p>
            </list-item>
          </list>
          <p><bold>CAVD.</bold> CAVD usually results from compound heterozygosity of a classic (severe, loss-of-function) <italic toggle="yes">CFTR</italic> pathogenic variant with a mild (retaining some function) <italic toggle="yes">CFTR</italic> pathogenic variant (e.g., the 5T allele; <xref ref-type="table" rid="cf.T.genotypephenotype_correlations">Table 2</xref>). However, some overlap exists between the CAVD phenotype and a very mild CF phenotype, with a small percentage of individuals with CAVD also reporting respiratory or pancreatic problems [<xref ref-type="bibr" rid="cf.REF.d_rk.1997.365">D&#x000f6;rk et al 1997</xref>, <xref ref-type="bibr" rid="cf.REF.gilljam.2004.174">Gilljam et al 2004</xref>]. The 5T allele may be associated with lung disease in adult females with CF-like clinical features [<xref ref-type="bibr" rid="cf.REF.noone.2000.1919">Noone et al 2000</xref>]. Thus, caution must be exercised in attempting to use genotype to predict the future course of individuals initially diagnosed with CAVD only.</p>
          <table-wrap id="cf.T.genotypephenotype_correlations" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Genotype-Phenotype Correlations</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1"><italic toggle="yes">CFTR</italic> Genotype&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2">Range of Phenotypes&#x000a0;<sup>2</sup></th>
                </tr>
                <tr>
                  <th headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1" id="hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">First Allele</th>
                  <th headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1" id="hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Second Allele<break/>(or Homozygous)</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Classic (e.g., p.Phe508del)</td>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Classic</td>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Classic &#x0003e;&#x0003e; non-classic</td>
                </tr>
                <tr>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Mild (e.g., p.Ala455Glu)</td>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Classic or mild</td>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Non-classic &#x0003e; classic</td>
                </tr>
                <tr>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">p.Arg117His / 5T</td>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Classic or mild</td>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Non-classic &#x0003e; classic</td>
                </tr>
                <tr>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">p.Arg117His / 7T</td>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Classic or mild</td>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Asymptomatic female or CAVD &#x0003e; non-classic</td>
                </tr>
                <tr>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">5T / 13TG or 12TG</td>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Classic or mild</td>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">CAVD or non-classic CF &#x0003e;&#x0003e; asymptomatic carrier</td>
                </tr>
                <tr>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">5T / 11TG</td>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Classic or mild</td>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Asymptomatic &#x0003e; CAVD</td>
                </tr>
                <tr>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">7T or 9T</td>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Classic or mild</td>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Asymptomatic</td>
                </tr>
                <tr>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">7T or 9T</td>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_1 hd_h_cf.T.genotypephenotype_correlations_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">7T or 9T</td>
                  <td headers="hd_h_cf.T.genotypephenotype_correlations_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Asymptomatic</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="cf.TF.2.1">
                <label>1. </label>
                <p>Patterns reflect dominant effect of "milder" alleles in compound heterozygotes. Classic alleles generally refer to Class I-III pathogenic variants; mild alleles refer to Class IV-V pathogenic variants exclusive of p.Arg117His and 5T alleles (see <xref ref-type="table" rid="cf.T.historical_classification_scheme_fo">Table 8</xref>).</p>
              </fn>
              <fn id="cf.TF.2.2">
                <label>2. </label>
                <p>Data derived from <xref ref-type="bibr" rid="cf.REF.kiesewetter.1993.274">Kiesewetter et al [1993]</xref>, <xref ref-type="bibr" rid="cf.REF.witt.1996.823">Witt et al [1996]</xref>, <xref ref-type="bibr" rid="cf.REF.brock.1998.47">Brock et al [1998]</xref>, <xref ref-type="bibr" rid="cf.REF.cuppens.1998.487">Cuppens et al [1998]</xref>, <xref ref-type="bibr" rid="cf.REF.mak.1999.2217">Mak et al [1999]</xref>, <xref ref-type="bibr" rid="cf.REF.wang.2002.2066">Wang et al [2002]</xref>, <xref ref-type="bibr" rid="cf.REF.mckone.2003.1671">McKone et al [2003]</xref>, <xref ref-type="bibr" rid="cf.REF.groman.2004.176">Groman et al [2004]</xref></p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="cf.Nomenclature">
          <title>Nomenclature</title>
          <p>Atypical cystic fibrosis, a term originally proposed to describe a disorder that presents with cystic fibrosis-like symptoms but is not caused by CFTR dysfunction, is sometimes used to denote mild or non-classic CF. However, use of the term in this way is confusing and strongly discouraged.</p>
        </sec>
        <sec id="cf.Prevalence">
          <title>Prevalence</title>
          <p>CF is the most common life-limiting autosomal recessive disorder in individuals of northern European background. The disease incidence of CF is 1:3200 live births in this population [<xref ref-type="bibr" rid="cf.REF.rosenstein.1998.589">Rosenstein &#x00026; Cutting 1998</xref>]. Approximately 30,000 affected persons live in the United States. The carrier frequency of individuals of northern European ancestry living in North America is 1:28 (see <xref ref-type="table" rid="cf.T.carrier_frequency_for_pathogenic_cf">Table 3</xref>).</p>
          <p>CF occurs with lower frequency in other ethnic and racial populations (1:15,000 African Americans, and 1:31,000 Asian Americans) [<xref ref-type="bibr" rid="cf.REF.rosenstein.1998.589">Rosenstein &#x00026; Cutting 1998</xref>].</p>
          <table-wrap id="cf.T.carrier_frequency_for_pathogenic_cf" orientation="portrait" position="anchor">
            <label>Table 3. </label>
            <caption>
              <p>Carrier Frequency for Pathogenic <italic toggle="yes">CFTR</italic> Alleles</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Population Group</th>
                  <th id="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Approximate Carrier Frequency</th>
                  <th id="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Ashkenazi Jewish</td>
                  <td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:29</td>
                  <td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="cf.REF.kerem.1997.35">Kerem et al [1997]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">North Americans of northern European background</td>
                  <td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:28</td>
                  <td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="cf.REF.hamosh.1998.255">Hamosh et al [1998]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">African American</td>
                  <td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:61</td>
                  <td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="cf.REF.hamosh.1998.255">Hamosh et al [1998]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Asian American</td>
                  <td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:118&#x000a0;<sup>1</sup></td>
                  <td headers="hd_h_cf.T.carrier_frequency_for_pathogenic_cf_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="cf.REF.rohlfs.2011.841">Rohlfs et al [2011]</xref>
                  </td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="cf.TF.3.1">
                <label>1. </label>
                <p>This carrier frequency is based on observed frequency of pathogenic variants in a tested population, it is not calculated from a population incidence.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="cf.Genetically_Related_Allelic_Disorders">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><italic toggle="yes">CFTR</italic>-related disorder (CFTR-RD) includes isolated pancreatitis and bronchiectasis due to heterozygous <italic toggle="yes">CFTR</italic> pathogenic variants in individuals who do not meet clinical diagnostic criteria for CF [<xref ref-type="bibr" rid="cf.REF.bombieri.2011.s86">Bombieri et al 2011</xref>].</p>
        <p><italic toggle="yes">CFTR</italic>-related metabolic syndrome (CRMS) is used to describe an infant with an elevated trypsinogen on newborn screening, sweat chloride values &#x02264;60 mEq/L, and up to two <italic toggle="yes">CFTR</italic> variants, at least one of which is not clearly categorized as a pathogenic variant and therefore not meeting diagnostic criteria for CF. These infants are typically asymptomatic, and knowledge of the natural history of CRMS continues to evolve [<xref ref-type="bibr" rid="cf.REF.borowitz.2009.s106">Borowitz et al 2009</xref>].</p>
        <p>An increased prevalence of <italic toggle="yes">CFTR</italic> pathogenic variants has been noted in individuals with idiopathic pancreatitis, bronchiectasis, allergic bronchopulmonary aspergillosis, and chronic rhinosinusitis [<xref ref-type="bibr" rid="cf.REF.nick.2005.513">Nick &#x00026; Rodman 2005</xref>, <xref ref-type="bibr" rid="cf.REF.weiss.2005.1456">Weiss et al 2005</xref>, <xref ref-type="bibr" rid="cf.REF.bombieri.2011.s86">Bombieri et al 2011</xref>, <xref ref-type="bibr" rid="cf.REF.ferec.2012.a009480">Ferec &#x00026; Cutting 2012</xref>].</p>
      </sec>
      <sec id="cf.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <sec id="cf.Cystic_Fibrosis_CF">
          <title>Cystic Fibrosis (CF)</title>
          <p><bold>Primary dysphagia</bold>
<bold>with chronic descending tracheal aspiration</bold> and <bold>primary gastroesophageal reflux (GER) with or without ascending tracheal aspiration.</bold> Both conditions can cause chronic cough in infancy and may be associated with failure to thrive. However, in infants without CF, the cough is often temporally associated with feedings; and steatorrhea is not associated with primary dysphagia or primary GER.</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="x-scid" document-type="chapter"><bold>Severe combined immunodeficiency</bold></related-object>
<bold>and other immunodeficiency disorders.</bold> Individuals with immunodeficiency may present with recurrent respiratory infections and chronic diarrhea in infancy. These individuals are also prone to non-respiratory infections (e.g., otitis media, cellulitis) not specifically associated with CF.</p>
          <p><bold>Asthma.</bold> CF and asthma both present with chronic cough and persistent wheeze following respiratory viral infections, allergen exposure, or exertion. However, individuals with asthma typically improve on asthma therapy, do not experience recurrent pneumonia, are not colonized with CF-related bacteria, have normal growth and weight gain, and do not have steatorrhea.</p>
          <p><bold>Congenital airway anomalies</bold> can cause chronic cough and wheezing during infancy similar to CF. Gastrointestinal or nutritional manifestations that are typically present in infants with CF are not seen in children with congenital airway anomalies. Stridor is not common in CF.</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="pcd" document-type="chapter"><bold>Primary ciliary dyskinesia</bold></related-object>
<bold>(PCD)</bold> is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic oto-sino-pulmonary disease. Individuals with PCD present with respiratory distress in infancy, cough and sputum production with recurrent pneumonias that may progress to chronic bronchiectasis, <italic toggle="yes">Pseudomonas aeruginosa</italic> or other opportunistic bacterial pathogens that may be cultured from airway secretions, and chronic sinus disease. Situs inversus is present in 50% of individuals with PCD; steatorrhea and failure to thrive are not associated with PCD. PCD is associated with pathogenic variants in multiple genes encoding different structural components of cilia and is inherited in an autosomal recessive manner.</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="sds" document-type="chapter"><bold>Shwachman-Diamond syndrome</bold></related-object>
<bold>(SDS</bold>) is characterized by exocrine pancreatic dysfunction with malabsorption, malnutrition, and growth failure. SDS can be distinguished from CF by the presence of hematologic abnormalities with single- or multi-lineage cytopenias, susceptibility to myelodysplasia syndrome (MDS) and acute myelogenous leukemia (AML), and skeletal abnormalities (most commonly chondrodysplasia or asphyxiating thoracic dystrophy). SDS is caused by biallelic pathogenic variants in <italic toggle="yes">SBDS</italic> and is inherited in an autosomal recessive manner.</p>
          <p><bold>Primary biliary atresia.</bold> Rarely, individuals with CF may present in infancy with symptoms of biliary obstruction without other clinically apparent GI or respiratory manifestations. Serum levels of immunoreactive trypsinogen and stool levels of elastase should be normal in primary biliary atresia, whereas CF liver disease is invariably associated with evidence of pancreatic duct obstruction.</p>
          <p><bold>Bronchiectasis with or without elevated sweat chloride.</bold> Pathogenic variants in <italic toggle="yes">SCNN1A</italic>, <italic toggle="yes">SCNN1B</italic>, and <italic toggle="yes">SCNN1G</italic> encoding the beta subunit of the epithelial sodium channel cause a non-classic CF phenotype [<xref ref-type="bibr" rid="cf.REF.sheridan.2005.3493">Sheridan et al 2005</xref>]. Individuals with <italic toggle="yes">SCNN1A</italic>, <italic toggle="yes">SCNN1B</italic>, or <italic toggle="yes">SCNN1G</italic> pathogenic variants may also have mild lung disease and elevated sweat chloride concentration.</p>
          <p><bold>Isolated hyperchlorhidrosis,</bold> characterized by elevated sweat chloride levels and failure to thrive, is caused by pathogenic variants in <italic toggle="yes">CA12</italic>, which encodes carbonic anhydrase XII [<xref ref-type="bibr" rid="cf.REF.feldshtein.2010.713">Feldshtein et al 2010</xref>].</p>
        </sec>
        <sec id="cf.Congenital_Absence_of_the_Vas_Deferen">
          <title>Congenital Absence of the Vas Deferens (CAVD)</title>
          <p>CAVD is part of the differential diagnosis of obstructive azoospermia, caused by obstruction to sperm outflow from the testes or ductular system. Obstructive azoospermia may be part of a syndrome or may be an isolated finding. Syndromes with obstructive azoospermia include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Young syndrome</bold> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/279000">OMIM</ext-link>), a progressive obstruction of the epididymis by inspissated secretions in males with chronic sinopulmonary infection. Males with Young syndrome do not have malformations of the vas deferens or epididymis. Molecular testing of individuals with Young syndrome indicates that this disorder is not caused by pathogenic variants in <italic toggle="yes">CFTR</italic> [<xref ref-type="bibr" rid="cf.REF.friedman.1995.1353">Friedman et al 1995</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Hereditary urogenital adysplasia</bold> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/277000">OMIM</ext-link>), an autosomal dominant disorder of variable expressivity and reduced penetrance. Females have a range of uterine anomalies; males may have Wolffian duct anomalies including unilateral or bilateral absence of the vas deferens; males and females may have unilateral or bilateral renal agenesis.</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="cf.Management">
        <title>Management</title>
        <sec id="cf.Evaluations_Following_Initial_Diagnos">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with <bold>cystic fibrosis (CF)</bold> the following evaluations are recommended.</p>
          <p>
            <bold>Respiratory</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Sinus CT to assess for pan sinusitis in individuals with chronic nasal congestion and/or recurrent sinusitis</p>
            </list-item>
            <list-item>
              <p>Pulmonary function testing (PFT), including infant PFT at specialized centers</p>
            </list-item>
            <list-item>
              <p>Chest radiographic examination to screen for bronchiectasis, or chest computed tomography (CT) examination as indicated for worsening symptoms or concern for progression</p>
            </list-item>
            <list-item>
              <p>Sputum culture in affected individuals who can expectorate a sputum sample, or culture of deep oropharyngeal swab in those who cannot</p>
            </list-item>
            <list-item>
              <p>Bronchoscopy with bronchoalveolar lavage to evaluate lower airway microbiology and inflammation as indicated</p>
            </list-item>
          </list>
          <p>
            <bold>Exocrine pancreatic insufficiency</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Fecal elastase</p>
            </list-item>
            <list-item>
              <p>Fecal fat content based on 72-hour stool collection</p>
            </list-item>
            <list-item>
              <p>Vitamin A, D, and E serum concentrations</p>
            </list-item>
            <list-item>
              <p>Prothrombin time and international normalized ratio (INR)</p>
            </list-item>
            <list-item>
              <p>Random glucose</p>
            </list-item>
          </list>
          <p>
            <bold>Overall clinical status / extent of disease</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>CBC with differential and cell count</p>
            </list-item>
            <list-item>
              <p>Serum electrolytes, BUN, creatinine</p>
            </list-item>
            <list-item>
              <p>Liver function tests (ALT, AST)</p>
            </list-item>
            <list-item>
              <p>Consultation with a genetic counselor</p>
            </list-item>
          </list>
          <p>To establish the extent of disease and needs in an individual diagnosed with <bold>congenital absence of the vas deferens (CAVD)</bold> referral to a urologist is recommended.</p>
        </sec>
        <sec id="cf.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <sec id="cf.Cystic_Fibrosis_CF_1">
            <title>Cystic Fibrosis (CF)</title>
            <p>
              <bold>Respiratory</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Inhaled dornase alfa in all individuals age &#x02265;6 years</p>
              </list-item>
              <list-item>
                <p>Inhaled hypertonic saline in all individuals age &#x02265;6 years</p>
              </list-item>
              <list-item>
                <p>Azithromycin in individuals age &#x02265;6 years with persistent <italic toggle="yes">Pseudomonas aeruginosa</italic> in airway cultures</p>
              </list-item>
              <list-item>
                <p>Inhaled tobramycin in individuals age &#x02265;6 years with lung disease (mild, moderate, or severe) and persistent <italic toggle="yes">P. aeruginosa</italic> in airway cultures</p>
              </list-item>
              <list-item>
                <p>Inhaled aztreonam in individuals age &#x02265;6 years with lung disease (mild, moderate, or severe) and persistent <italic toggle="yes">P. aeruginosa</italic> in airway cultures</p>
              </list-item>
              <list-item>
                <p>Ibuprofen in individuals age 6-17 years with FEV<sub>1</sub> &#x02265;60% predicted</p>
              </list-item>
              <list-item>
                <p>Recommended sequence for inhaled medications:</p>
                <list list-type="order">
                  <list-item>
                    <label>1</label>
                    <p>Bronchodilator</p>
                  </list-item>
                  <list-item>
                    <label>2</label>
                    <p>Hypertonic saline</p>
                  </list-item>
                  <list-item>
                    <label>3</label>
                    <p>Dornase alfa</p>
                  </list-item>
                  <list-item>
                    <label>4</label>
                    <p>Airway clearance</p>
                  </list-item>
                  <list-item>
                    <label>5</label>
                    <p>An aerosolized antibiotic</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>Ivacaftor for individuals age &#x02265;2 years who are heterozygous for p.Gly551Asp and other specific pathogenic variants</p>
              </list-item>
              <list-item>
                <p>Ivacaftor/lumacaftor combined therapy for individuals age &#x02265;12 years who are homozygous for p.Phe508del</p>
              </list-item>
              <list-item>
                <p>Lung or heart/lung transplantation; an option for some individuals with severe disease</p>
              </list-item>
              <list-item>
                <p>Topical steroids, antibiotics, and/or surgical intervention if required for nasal/sinus symptoms</p>
              </list-item>
            </list>
            <p>
              <bold>Exocrine pancreatic insufficiency</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Oral pancreatic enzyme replacement with meals</p>
              </list-item>
              <list-item>
                <p>Nutritional therapy that may include breast milk, special infant formulas, supplemental feeding, salt supplementation, fat-soluble vitamin supplements, and zinc</p>
              </list-item>
              <list-item>
                <p>Management of CF-related diabetes mellitus with endocrinology consultation and (if required) glucose monitoring and insulin therapy</p>
              </list-item>
            </list>
            <p><bold>Gastrointestinal.</bold> Meconium ileus and distal intestinal obstructive syndrome requires surgical evaluation and management.</p>
            <p>
              <bold>Liver disease</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Biliary sludging or frank obstruction, and associated hepatic inflammation, are treated with oral ursodiol.</p>
              </list-item>
              <list-item>
                <p>Liver transplant indications include progressive hepatic dysfunction, intractable variceal bleeding, and hepatopulmonary and portopulmonary syndromes</p>
              </list-item>
            </list>
            <p><bold>Fertility.</bold> Assisted reproductive technologies include microscopic sperm aspiration from the epididymal remnant in conjunction with in vitro fertilization or artificial insemination using donor sperm.</p>
          </sec>
          <sec id="cf.Congenital_Absence_of_the_Vas_Deferen_1">
            <title>Congenital Absence of the Vas Deferens (CAVD)</title>
            <p>Assisted reproductive technologies include microscopic sperm aspiration from the epididymal remnant in conjunction with in vitro fertilization or artificial insemination using donor sperm.</p>
          </sec>
        </sec>
        <sec id="cf.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations &#x02013; Cystic Fibrosis</title>
          <p>
            <bold>Respiratory</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>A variety of airway clearance techniques (ACTs) can mobilize airway secretions, minimize airway obstruction, and reduce airway infections. ACTs include manual chest percussion with postural drainage, hand-held devices (e.g., flutter valve, or Acapella<sup>&#x000ae;</sup>), and inflatable vest therapy devices that vibrate the chest wall. These treatments are most effective when used at least twice daily.</p>
            </list-item>
            <list-item>
              <p>Dornase alfa and hypertonic saline help mobilize airway secretions in individuals age six years or older.</p>
            </list-item>
            <list-item>
              <p>Airway clearance should be used in conjunction with inhaled medications given in a standard sequence:</p>
              <list list-type="order">
                <list-item>
                  <label>1</label>
                  <p>Bronchodilator</p>
                </list-item>
                <list-item>
                  <label>2</label>
                  <p>Hypertonic saline</p>
                </list-item>
                <list-item>
                  <label>3</label>
                  <p>Dornase alfa</p>
                </list-item>
                <list-item>
                  <label>4</label>
                  <p>Airway clearance</p>
                </list-item>
                <list-item>
                  <label>5</label>
                  <p>Inhaled corticosteroids and/or long-acting beta agonist (for select individuals)</p>
                </list-item>
                <list-item>
                  <label>6</label>
                  <p>Aerosolized antibiotic</p>
                </list-item>
              </list>
              <p>The rationale for this sequence is to open the airway, decrease sputum viscosity, promote expectoration of secretions, and then deliver anti-inflammatory treatments and/or antibiotics as widely and deeply as possible within the bronchial tree.</p>
            </list-item>
            <list-item>
              <p>Aggressive antibiotic treatment at the time of initial isolation of <italic toggle="yes">P. aeruginosa</italic> from cultured airway secretions helps prevent chronic airway infection.</p>
            </list-item>
            <list-item>
              <p>All routine immunizations should be given at the recommended times. Especially important are vaccines that protect against microorganisms associated with pulmonary manifestations, including pertussis, measles, varicella, <italic toggle="yes">Haemophilus influenzae</italic> type B, and <italic toggle="yes">Streptococcus pneumoniae</italic>.</p>
            </list-item>
            <list-item>
              <p>Influenza vaccine should be administered annually in infants age six months and older. Note: (1) Because the influenza vaccine may not be fully protective, consider immunizing an affected individual&#x02019;s entire family. (2) CF individuals with suspected influenza should receive anti-viral medications targeted toward influenza A and B.</p>
            </list-item>
            <list-item>
              <p>Anti-RSV monoclonal antibody (Synagis<sup>&#x000ae;</sup>) should be considered for infants up to age 12 months for the duration of the local RSV season, particularly in individuals with ongoing pulmonary symptoms.</p>
            </list-item>
            <list-item>
              <p>Physical activity, exercise, and conditioning help maintain bone health and improve airway clearance.</p>
            </list-item>
          </list>
          <p>
            <bold>Exocrine pancreatic insufficiency</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Pancreatic enzyme replacement and supplementation of fat-soluble vitamins</p>
            </list-item>
            <list-item>
              <p>High-calorie, high-fat nutritional supplements</p>
            </list-item>
            <list-item>
              <p>Consultation with a nutritionist specializing in CF</p>
            </list-item>
            <list-item>
              <p>Extra salt and water for hydration and salt losses in hot dry climates</p>
            </list-item>
          </list>
        </sec>
        <sec id="cf.Surveillance__Cystic_Fibrosis">
          <title>Surveillance &#x02013; Cystic Fibrosis</title>
          <p>
            <bold>Respiratory</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Newborns are examined monthly by a CF care provider for the first six months of life and then bimonthly until age one year.</p>
            </list-item>
            <list-item>
              <p>Individuals age one year and older should be examined quarterly by a CF care provider to monitor for subtle changes in physical examination that are not yet manifest as symptoms.</p>
            </list-item>
            <list-item>
              <p>Culture respiratory tract secretions at least four times yearly. Some individuals may benefit from more frequent visits and respiratory tract surveillance cultures (see <xref ref-type="sec" rid="cf.Therapies_Under_Investigation">Therapies Under Investigation</xref>).</p>
            </list-item>
            <list-item>
              <p>Pulmonary function studies, chest radiographic examination, and at least annual blood tests for electrolytes, fat soluble vitamin levels, and IgE levels are appropriate.</p>
            </list-item>
            <list-item>
              <p>Bronchoscopy and chest CT examination are indicated for individuals with symptoms and signs of lung disease who fail to respond to intervention.</p>
            </list-item>
          </list>
          <p>
            <bold>Exocrine pancreatic insufficiency</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Weight gain and caloric intake are monitored monthly in newborns until age six months.</p>
            </list-item>
            <list-item>
              <p>Fecal elastase may need to be repeated during the first year of life, particularly if infants have signs or symptoms of malabsorption or inadequate weight gain.</p>
            </list-item>
            <list-item>
              <p>Measure oral glucose tolerance annually after age ten years during a period of stable health. Plasma glucose is measured fasting and two hours after an oral glucose load of 1.75 g/kg, or 75 g maximum.</p>
            </list-item>
            <list-item>
              <p>Evaluate bone mineral density in adolescence.</p>
            </list-item>
          </list>
          <p><bold>Liver disease.</bold> Annual screening of liver function tests and liver ultrasound to monitor progression of liver disease is appropriate.</p>
        </sec>
        <sec id="cf.AgentsCircumstances_to_Avoid__Cystic">
          <title>Agents/Circumstances to Avoid &#x02013; Cystic Fibrosis</title>
          <p>Avoid the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Respiratory irritants (e.g., smoke, dust)</p>
            </list-item>
            <list-item>
              <p>Individuals with respiratory infections</p>
            </list-item>
            <list-item>
              <p>Dehydration; add extra salt and water to diet in hot, dry climates because of perspiration-related salt losses (see <xref ref-type="sec" rid="cf.Prevention_of_Primary_Manifestations">Prevention of Primary Manifestations</xref>).</p>
            </list-item>
          </list>
        </sec>
        <sec id="cf.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate apparently asymptomatic older and younger sibs of a proband/at-risk relatives in order to identify as early as possible those who should be referred to a cystic fibrosis center for initiation of treatment and preventive measures.</p>
          <p>Evaluations can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing if the pathogenic variants in the family are known;</p>
            </list-item>
            <list-item>
              <p>Sweat chloride testing if the pathogenic variants in the family are not known.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="cf.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="cf.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Pregnancies are well tolerated with improved nutrition, improved pulmonary treatment, aggressive management of infections, and a multidisciplinary care team, especially in women with mild to moderate disease. Pregnancy is not associated with an increased risk of death [<xref ref-type="bibr" rid="cf.REF.goss.2003.1460">Goss et al 2003</xref>]. In all studies published to date, the most important predictors of pregnancy outcome are the severity of maternal pulmonary impairment and nutritional status; deterioration during pregnancy may precipitate preterm delivery.</p>
          <list list-type="bullet">
            <list-item>
              <p>Females with CF of reproductive age should receive preconception counseling and take steps to optimize health prior to pregnancy.</p>
            </list-item>
            <list-item>
              <p>The management of pregnancy and the immediate post-partum period for a woman with CF requires a dietician, members of the CF team, and a maternal fetal medicine specialist.</p>
            </list-item>
            <list-item>
              <p>Maternal nutritional status and weight gain should be monitored and optimized aggressively and pulmonary exacerbations should be treated early.</p>
            </list-item>
            <list-item>
              <p>Traditional screening paradigms for gestational diabetes mellitus may not be useful in pregnancies of women with CF; therefore, screening at each trimester of pregnancy has been suggested to improve the detection of diabetes mellitus.</p>
            </list-item>
            <list-item>
              <p>As in pregnancies of women with other forms of diabetes mellitus, fetal outcome is optimized when glycemic control is achieved prior to pregnancy.</p>
            </list-item>
            <list-item>
              <p>Mode of delivery is based on usual obstetric indications.</p>
            </list-item>
          </list>
        </sec>
        <sec id="cf.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Ursodeoxycholic acid may be cytoprotective and increase bile flow to improve hepatic enzyme levels, bile drainage, liver histology, and nutritional status [<xref ref-type="bibr" rid="cf.REF.desmond.2007.1402">Desmond et al 2007</xref>, <xref ref-type="bibr" rid="cf.REF.cheng.2012.cd000222">Cheng et al 2012</xref>, <xref ref-type="bibr" rid="cf.REF.leeuwen.2014.69">Leeuwen et al 2014</xref>]. However, whether ursodiol therapy can prevent progression of liver disease in the subset of individuals with CF who are at risk for this complication is uncertain [<xref ref-type="bibr" rid="cf.REF.brigman.2006.484">Brigman &#x00026; Feranchak 2006</xref>, <xref ref-type="bibr" rid="cf.REF.leeuwen.2014.69">Leeuwen et al 2014</xref>].</p>
          <p><italic toggle="yes">CFTR</italic> pathogenic variant-specific candidate drugs:</p>
          <list list-type="bullet">
            <list-item>
              <p>CF correctors such as VX-661 are small-molecule therapies being developed to increase the quantity of functional CFTR protein at the cell surface in individuals with specific <italic toggle="yes">CFTR</italic> pathogenic variants (including the most common CF variant, p.Phe508del).</p>
            </list-item>
            <list-item>
              <p>Inhaled dry powder mannitol has demonstrated relative sustained improvement in lung function in both European and American trials [<xref ref-type="bibr" rid="cf.REF.bilton.2011.1071">Bilton at al 2011</xref>, <xref ref-type="bibr" rid="cf.REF.aiken.2012.2308">Aiken et al 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>Alternate ion channel regulation is being investigated as a strategy to restore airway surface liquid.</p>
            </list-item>
          </list>
          <p><bold>Gene therapy.</bold> Gene therapy is in early clinical trials. Gene therapy is not able to control or treat the symptoms related to CF at this time [<xref ref-type="bibr" rid="cf.REF.prickett.2013.255">Prickett &#x00026; Jain 2013</xref>]</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="cf.Other">
          <title>Other</title>
          <p>While there has been much interest in developing active and passive immunization strategies against <italic toggle="yes">Pseudomonas aeruginosa</italic>, an effective vaccine against <italic toggle="yes">P. aeruginosa</italic> has not yet been developed.</p>
        </sec>
      </sec>
      <sec id="cf.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="cf.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Cystic fibrosis (CF) and congenital absence of the vas deferens (CAVD) are inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="cf.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband with CF</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">CFTR</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are generally asymptomatic.</p>
            </list-item>
            <list-item>
              <p>On rare occasions, a parent may be diagnosed as affected subsequent to the diagnosis of the child.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband with CF</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are generally asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband with CF</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Females with CF can be fertile.</p>
            </list-item>
            <list-item>
              <p>Males with CF may conceive children through assisted reproductive technologies (ART).</p>
            </list-item>
            <list-item>
              <p>Offspring of a male or female proband with CF inherit one <italic toggle="yes">CFTR</italic> pathogenic variant from their affected parent.</p>
            </list-item>
            <list-item>
              <p>The risk that a child will inherit a second <italic toggle="yes">CFTR</italic> pathogenic variant depends on the reproductive partner's genetic status. If the reproductive partner is heterozygous for a <italic toggle="yes">CFTR</italic> pathogenic variant, offspring are at a 50% risk of being affected and a 50% risk of being obligate heterozygotes.</p>
            </list-item>
          </list>
          <p>
            <bold>Parents, sibs, and offspring of a proband with CAVD</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Males with CAVD may conceive children through assisted reproductive technologies (ART).</p>
            </list-item>
            <list-item>
              <p>The risk to the relatives of a proband with CAVD depends on the parental genotypes and cannot readily be predicted without this information.</p>
            </list-item>
            <list-item>
              <p>Molecular genetic testing is most informative when the CAVD-causing <italic toggle="yes">CFTR</italic> variants have been identified in the proband. Men with CAVD may have only one identifiable <italic toggle="yes">CFTR</italic> variant, complicating the testing and interpretation of results in their family members.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> Each sib of an individual known to be heterozygous for a <italic toggle="yes">CFTR</italic> pathogenic variant is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="cf.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">CFTR</italic> pathogenic variants in the family.</p>
          <p>If the proband is deceased and molecular testing was not performed, it is appropriate to attempt to obtain an available tissue sample for <italic toggle="yes">CFTR</italic> molecular testing. If molecular testing cannot be done on the proband&#x02019;s tissue, it is appropriate to offer molecular testing to at-risk family members. Individuals in whom a <italic toggle="yes">CFTR</italic> pathogenic variant is not identified have a reduced carrier risk (see <xref ref-type="table" rid="cf.T.residual_risk_of_being_a_carrier_fo">Table 4</xref>).</p>
          <p>5T and TG tract typing should not be included in a routine carrier screen. The 5T/TG tract analysis is not able to provide a specific risk figure for developing symptoms or having a child who develops symptoms of non-classic CF or CAVD; it is able to assign risk as "increased" or "decreased."</p>
          <p>If an individual has the p.Arg117His pathogenic variant, reflex testing for the variants 5T/7T/9T is recommended. If the individual has the 5T allele, family studies are recommended to determine if the 5T allele is in <italic toggle="yes">cis</italic> configuration or <italic toggle="yes">trans</italic> configuration with the p.Arg117His allele. An individual with p.Phe508del and 5T/11TG is highly unlikely to develop non-classic CF. An individual with p.Phe508del and 5T/12TG or p.Phe508del and 5T/13TG may rarely develop CAVD or non-classic CF [<xref ref-type="bibr" rid="cf.REF.groman.2004.176">Groman et al 2004</xref>].</p>
          <p>Multiple naming systems are still in use for <italic toggle="yes">CFTR</italic> pathogenic variants. When ordering targeted testing for familial <italic toggle="yes">CFTR</italic> variants, it is important to know whether a particular variant is named using the legacy or HGVS convention (see <xref ref-type="bibr" rid="cf.REF.berwouts.2011.1197">Berwouts et al [2011]</xref> for review).</p>
          <table-wrap id="cf.T.residual_risk_of_being_a_carrier_fo" orientation="portrait" position="anchor">
            <label>Table 4. </label>
            <caption>
              <p>Residual Risk of Being a Carrier for a <italic toggle="yes">CFTR</italic> Pathogenic Variant if Molecular Testing Does Not Detect a Pathogenic Variant</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_1">Prior Risk of<break/>Being a Carrier</th>
                  <th id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" valign="middle" colspan="10" align="left" scope="colgroup" rowspan="1">Residual Risk (%) of Being a Carrier if the Pathogenic Variant Detection Rate is:</th>
                </tr>
                <tr>
                  <th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">30%</th>
                  <th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">40%</th>
                  <th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">50%</th>
                  <th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">60%</th>
                  <th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">70%</th>
                  <th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_6" valign="middle" align="left" scope="col" rowspan="1" colspan="1">75%</th>
                  <th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_7" valign="middle" align="left" scope="col" rowspan="1" colspan="1">80%</th>
                  <th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_8" valign="middle" align="left" scope="col" rowspan="1" colspan="1">85%</th>
                  <th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_9" valign="middle" align="left" scope="col" rowspan="1" colspan="1">90%</th>
                  <th headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2" id="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_10" valign="middle" align="left" scope="col" rowspan="1" colspan="1">96%</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>2/3</bold>
                  </td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">58.3%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">54.5%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">50.0%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">44.4%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_5" valign="middle" align="left" rowspan="1" colspan="1">37.5%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_6" valign="middle" align="left" rowspan="1" colspan="1">33.3%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_7" valign="middle" align="left" rowspan="1" colspan="1">28.6%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_8" valign="middle" align="left" rowspan="1" colspan="1">23.1%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_9" valign="middle" align="left" rowspan="1" colspan="1">16.7%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_10" valign="middle" align="left" rowspan="1" colspan="1">7.4%</td>
                </tr>
                <tr>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>1/2</bold>
                  </td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">41.2%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">37.5%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">33.3%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">28.6%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_5" valign="middle" align="left" rowspan="1" colspan="1">23.1%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_6" valign="middle" align="left" rowspan="1" colspan="1">20.0%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_7" valign="middle" align="left" rowspan="1" colspan="1">16.7%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_8" valign="middle" align="left" rowspan="1" colspan="1">13.0%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_9" valign="middle" align="left" rowspan="1" colspan="1">9.1%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_10" valign="middle" align="left" rowspan="1" colspan="1">3.8%</td>
                </tr>
                <tr>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>1/4</bold>
                  </td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">18.9%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">16.7%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">14.3%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">11.8%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_5" valign="middle" align="left" rowspan="1" colspan="1">9.1%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_6" valign="middle" align="left" rowspan="1" colspan="1">7.7%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_7" valign="middle" align="left" rowspan="1" colspan="1">6.3%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_8" valign="middle" align="left" rowspan="1" colspan="1">4.8%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_9" valign="middle" align="left" rowspan="1" colspan="1">3.2%</td>
                  <td headers="hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_1_2 hd_h_cf.T.residual_risk_of_being_a_carrier_fo_1_1_2_10" valign="middle" align="left" rowspan="1" colspan="1">1.3%</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>See <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="cf-Table4a.pdf" content-type="local-data">Table 4a</inline-supplementary-material> (pdf) for residual risk of being a carrier for other values of prior risk.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="cf.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="cf.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on testing at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of carrier testing, potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="cf.Population_Screening">
          <title>Population Screening</title>
          <p>Screening for CF carrier status is offered to some couples as part of routine prenatal care. The ACMG Subcommittee on Cystic Fibrosis Screening recommends offering CF carrier screening to individuals of northern European background and Ashkenazi Jews, and making carrier screening available to other ethnic groups. The Subcommittee recommends a pan ethnic panel including 23 pathogenic variants that includes the majority of CF-causing pathogenic variants with an allele frequency of greater than 0.1% in the general US population (<xref ref-type="table" rid="cf.T.recommended_panel_of_pathogenic_var">Table 6</xref>) [<xref ref-type="bibr" rid="cf.REF.grody.2001">Grody et al 2001</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/gim/journal/v3/n2/full/gim200129a.html">full text</ext-link>).</p>
          <p>The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://link.springer.com/article/10.1007/s10897-013-9636-9/fulltext.html">NSGC Practice Guideline</ext-link> recommends that carrier testing for CF be offered to all women of reproductive age, regardless of ancestry; preferably before conception. Pan ethnic panels that include pathogenic variants more commonly identified in minority populations are appropriate to consider for individuals of non-northern European descent. See <xref ref-type="sec" rid="cf.Carrier_Heterozygote_Detection">Carrier Detection</xref> for information on interpretation of results of CF carrier testing.</p>
          <p>Individuals with no family history of CF and negative carrier testing have a reduced carrier risk. <xref ref-type="table" rid="cf.T.residual_risk_to_an_individual_with">Table 5</xref> provides calculations of the residual risk of being a carrier based on the pathogenic variant detection rate of the test method used and the individual's a priori risk of being a carrier. The laboratory should be provided with complete and accurate information regarding the patient's ethnicity and family history of CF to facilitate accurate calculation of residual risk.</p>
          <table-wrap id="cf.T.residual_risk_to_an_individual_with" orientation="portrait" position="anchor">
            <label>Table 5. </label>
            <caption>
              <p>Residual Risk to an Individual with No Family History of a <italic toggle="yes">CFTR</italic>-Related Disorder of Being a Carrier (Heterozygote) if Molecular Genetic Testing Does Not Detect a Pathogenic Variant</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_1">Prior Risk of<break/>Being a Carrier</th>
                  <th id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" valign="middle" colspan="10" align="left" scope="colgroup" rowspan="1">Residual Risk (%) of Being a Carrier if the Pathogenic Variant Detection Rate is:</th>
                </tr>
                <tr>
                  <th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">30%</th>
                  <th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">40%</th>
                  <th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">50%</th>
                  <th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">60%</th>
                  <th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">70%</th>
                  <th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_6" valign="middle" align="left" scope="col" rowspan="1" colspan="1">75%</th>
                  <th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_7" valign="middle" align="left" scope="col" rowspan="1" colspan="1">80%</th>
                  <th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_8" valign="middle" align="left" scope="col" rowspan="1" colspan="1">85%</th>
                  <th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_9" valign="middle" align="left" scope="col" rowspan="1" colspan="1">90%</th>
                  <th headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2" id="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_10" valign="middle" align="left" scope="col" rowspan="1" colspan="1">96%</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>1/28 (3.57%)</bold>
                  </td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">2.5%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">2.2%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">1.8%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">1.5%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_5" valign="middle" align="left" rowspan="1" colspan="1">1.1%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_6" valign="middle" align="left" rowspan="1" colspan="1">0.9%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_7" valign="middle" align="left" rowspan="1" colspan="1">0.7%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_8" valign="middle" align="left" rowspan="1" colspan="1">0.6%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_9" valign="middle" align="left" rowspan="1" colspan="1">0.4%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_10" valign="middle" align="left" rowspan="1" colspan="1">0.15%</td>
                </tr>
                <tr>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>1/60 (1.7%)</bold>
                  </td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">1.2%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">1.0%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_3" valign="middle" align="left" rowspan="1" colspan="1">0.8%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_4" valign="middle" align="left" rowspan="1" colspan="1">0.7%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_5" valign="middle" align="left" rowspan="1" colspan="1">0.5%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_6" valign="middle" align="left" rowspan="1" colspan="1">0.4%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_7" valign="middle" align="left" rowspan="1" colspan="1">0.3%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_8" valign="middle" align="left" rowspan="1" colspan="1">0.3%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_9" valign="middle" align="left" rowspan="1" colspan="1">0.2%</td>
                  <td headers="hd_h_cf.T.residual_risk_to_an_individual_with_1_1_1_2 hd_h_cf.T.residual_risk_to_an_individual_with_1_1_2_10" valign="middle" align="left" rowspan="1" colspan="1">0.06%</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
          <p><bold>For more information,</bold> see the American College of Medical Genetics Carrier Screening ACT Sheets <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.acmg.net/StaticContent/ACT/CF_Mutation_not_R117H.pdf">C<italic toggle="yes">FTR</italic> Mutations except R117H</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.acmg.net/StaticContent/ACT/ACT_CFcarrier_R117H.pdf">Cystic Fibrosis R117H</ext-link>, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.acmg.net/StaticContent/ACT/CF_No_mutation.pdf">No Mutations Detected by Carrier Screening</ext-link>.</p>
        </sec>
        <sec id="cf.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>High-risk pregnancies.</bold> Once the <italic toggle="yes">CFTR</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for CF are possible.</p>
          <p><bold>Indeterminate-risk pregnancies.</bold> Amniotic fluid digestive enzyme analysis may be helpful for prenatal diagnosis in pregnancies of indeterminate risk following <italic toggle="yes">CFTR</italic> analysis [<xref ref-type="bibr" rid="cf.REF.oca.2009.2214">Oca et al 2009</xref>].</p>
          <p><bold>Low-risk pregnancies.</bold> The finding of fetal echogenic bowel and/or dilated bowel on ultrasound examination is associated with an increased risk for CF in a pregnancy previously not known to be at increased risk for CF. <xref ref-type="bibr" rid="cf.REF.scotet.2010.592.e1">Scotet et al [2010]</xref> found a 6.7% incidence of CF in 289 fetuses with the prenatal diagnosis of Grade 3 echogenic bowel, defined as echogenicity similar to or greater than that of surrounding fetal bone and/or intestinal dilation. In this situation, genetic counseling of the parents regarding the risk for CF is appropriate, followed by <italic toggle="yes">CFTR</italic> molecular genetic testing of the parents and/or the fetus, depending on the gestational age of the pregnancy and the decision of the parents. Based on the pathogenic variant detection rate of the test method used, the risk for CF when only one pathogenic variant is identified in the fetus can be calculated [<xref ref-type="bibr" rid="cf.REF.bosco.1999.1020">Bosco et al 1999</xref>, <xref ref-type="bibr" rid="cf.REF.hodge.1999.329">Hodge et al 1999</xref>].</p>
        </sec>
      </sec>
      <sec id="cf.Resources">
        <title>Resources</title>
      </sec>
      <sec id="cf.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">CFTR</italic> is 230 kb long and contains 27 coding exons. It produces a 6.5-kb mRNA product.</p>
        <p><bold>Pathogenic variants.</bold> More than 1000 <italic toggle="yes">CFTR</italic> variants have been reported. Almost all are missense variants or small (1-84 bp) deletions. The most common pathogenic variant is p.Phe508del, accounting for an estimated 30%-80% (depending on the ethnic group) of pathogenic variants. <xref ref-type="table" rid="cf.T.recommended_panel_of_pathogenic_var">Table 6</xref> lists the panel of 23 alleles recommended by the American College of Medical Genetics for routine diagnostic and carrier testing [<xref ref-type="bibr" rid="cf.REF.watson.2004.387">Watson et al 2004</xref>]. <xref ref-type="table" rid="cf.T.ten_most_common_cftr_pathogenic_var">Table 7</xref> lists ten of the most common <italic toggle="yes">CFTR</italic> pathogenic variants. The Clinical and Functional Translation of CFTR (CFTR2) website provides information about whether a pathogenic variant causes CF when combined with another CF-causing pathogenic variant and about the sweat chloride, lung function, pancreatic status, and pseudomonas infection rates in individuals in the CFTR2 database with specific pathogenic variants. Information on the CFTR2 website is updated as further analysis is completed (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cftr2.org">www.cftr2.org</ext-link>).</p>
        <p>Not all reported <italic toggle="yes">CFTR</italic> pathogenic variants are proven by population or functional studies to be pathogenic or CF-causing. The disease liability of missense variants is particularly difficult to determine from case reports [<xref ref-type="bibr" rid="cf.REF.sosnay.2013.1160">Sosnay et al 2013</xref>].</p>
        <p>Resources for information about <italic toggle="yes">CFTR</italic> variants include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sickkids.ca/search/search.aspx?SearchTerm=cftr1">Sick Kids</ext-link>
            </p>
          </list-item>
          <list-item>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cftr2.org/">CFTR2</ext-link>
            </p>
          </list-item>
          <list-item>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.umd.be/CFTR/">UMD-<italic toggle="yes">CFTR</italic> Knowledgebase</ext-link>
            </p>
          </list-item>
          <list-item>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/">ClinVar-NCBI</ext-link>
            </p>
          </list-item>
        </list>
        <table-wrap id="cf.T.recommended_panel_of_pathogenic_var" orientation="portrait" position="anchor">
          <label>Table 6. </label>
          <caption>
            <p>Recommended Panel of Pathogenic Variants for General Population CF Carrier Screening</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(---&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change<break/>(---&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequence</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.254G&#x0003e;A</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly85Glu<break/>(G85E)</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_3" rowspan="24" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000492.3">NM_000492.3</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.350G&#x0003e;A</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg117H<break/>(R117H)</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1000C&#x0003e;T</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg334Typ<break/>(R334W)</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1040G&#x0003e;C</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg347Pro<break/>(R347P)</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1364C&#x0003e;A</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala455Glu<break/>(A455E)</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1624G&#x0003e;T</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly542Ter<break/>(G542X)</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1652G&#x0003e;A</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly551Asp<break/>(G551D)</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1657C&#x0003e;T</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg553Ter<break/>(R553X)</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1679G&#x0003e;C</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg560Thr<break/>(R560T)</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.3484C&#x0003e;T</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg1162Ter<break/>(R1162X)</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.3846G&#x0003e;A</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Trp1282Ter<break/>(W1282X)</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.3909C&#x0003e;G</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asn1303Lys <break/>(N1303K)</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.489+1G&#x0003e;T <break/>(621+1G&#x0003e;T)</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.579+1G&#x0003e;T<break/>(711+1G&#x0003e;T)</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1519_1521delATC</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ile507del<break/>(&#x00394;I507)</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1521_1523delCTT</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Phe508del<break/>(&#x00394;F508)</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1585-1G&#x0003e;A <break/>(1717-1&#x0003e;A)</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1766+1G&#x0003e;A <break/>(1898+1G&#x0003e;A)</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2052delA <break/>(2184delA)</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2657+5G&#x0003e;A <break/>(2789+5G&#x0003e;A)</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2988+1G&#x0003e;A <break/>(3120+1G&#x0003e;A)</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.3527delC <break/>(3659delC)</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.3718-2477C&#x0003e;T<break/>(3849+10kbC&#x0003e;T)</td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">c.1210-12T[5_9]<break/>(5T/7T/9T)&#x000a0;<sup>2</sup></td>
                <td headers="hd_h_cf.T.recommended_panel_of_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="cf.TF.6.1">
              <label>1. </label>
              <p>Legacy nomenclature</p>
            </fn>
            <fn id="cf.TF.6.2">
              <label>2. </label>
              <p>Recommended as a reflex test when p.Arg117His is detected</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <table-wrap id="cf.T.ten_most_common_cftr_pathogenic_var" orientation="portrait" position="anchor">
          <label>Table 7. </label>
          <caption>
            <p>Ten Most Common <italic toggle="yes">CFTR</italic> Pathogenic Variants in Individuals of Northern European Background</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Pathogenic Variant</th>
                <th id="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Relative Frequency</th>
                <th id="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Pathogenic Variant Functional Class&#x000a0;<sup>1,&#x000a0;2</sup></th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">p.Phe508del</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">66.0%</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">II</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">p.Gly542Ter</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">2.4%</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">I</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">p.Gly551Asp</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1.6%</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">III</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">p.Asn1303Lys</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1.3%</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">II</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">p.Typ1282Ter</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1.2%</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">I</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">p.Arg553Ter</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0.7%</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">I</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.489+1G&#x0003e;T</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0.7%</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">I</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1585-1G&#x0003e;A</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0.6%</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">I</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">p.Arg117His</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0.3%</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">IV</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">p.Arg1162Ter</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0.3%</td>
                <td headers="hd_h_cf.T.ten_most_common_cftr_pathogenic_var_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Not clear&#x000a0;<sup>3</sup></td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Based on <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.genet.sickkids.on.ca/">www.genet.sickkids.on.ca</ext-link> and <xref ref-type="bibr" rid="cf.REF.mckone.2003.1671">McKone et al [2003]</xref></p>
            </fn>
            <fn id="cf.TF.7.1">
              <label>1. </label>
              <p>For information on phenotypic expression and functional studies, see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cftr2.org">www.cftr2.org</ext-link>.</p>
            </fn>
            <fn id="cf.TF.7.2">
              <label>2. </label>
              <p>See <xref ref-type="table" rid="cf.T.historical_classification_scheme_fo">Table 8</xref>.</p>
            </fn>
            <fn id="cf.TF.7.3">
              <label>3. </label>
              <p>Transcript is stable; truncated protein is probably misfolded; therefore, likely Class II.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> Cystic fibrosis transmembrane conductance regulator (<italic toggle="yes">CFTR</italic>) is a 1480-amino acid integral membrane protein that functions as a regulated chloride channel in epithelia.</p>
        <p><bold>Abnormal gene product.</bold> Pathogenic variants can affect the CFTR protein quantitatively, qualitatively, or both. <xref ref-type="table" rid="cf.T.historical_classification_scheme_fo">Table 8</xref> illustrates the historical classification scheme for the functional consequences of <italic toggle="yes">CFTR</italic> pathogenic variants. Several pathogenic variants actually cross several categories in their effects. Recently, with the advent of molecular-based treatments (see <xref ref-type="sec" rid="cf.Therapies_Under_Investigation">Therapies Under Investigation</xref>), the necessary classification categories have been reduced to two: reduced production and reduced function [<xref ref-type="bibr" rid="cf.REF.cutting.2015.45">Cutting 2015</xref>].</p>
        <table-wrap id="cf.T.historical_classification_scheme_fo" orientation="portrait" position="anchor">
          <label>Table 8. </label>
          <caption>
            <p>Historical Classification Scheme for <italic toggle="yes">CFTR</italic> Pathogenic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Pathogenic<break/>Variant<break/>Class</th>
                <th id="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Effect of Pathogenic Variant on CFTR Protein&#x000a0;<sup>1</sup></th>
                <th id="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Mechanisms</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">I</td>
                <td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Reduced or absent synthesis</td>
                <td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Nonsense, frameshift, or splice junction variants</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">II</td>
                <td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Block in protein processing</td>
                <td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Missense variants, amino acid deletions</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">III</td>
                <td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Block in regulation of CFTR chloride channel</td>
                <td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Missense variants</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">IV</td>
                <td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Altered conductance of CFTR chloride channel</td>
                <td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Missense variants</td>
              </tr>
              <tr>
                <td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">V</td>
                <td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Reduced synthesis/trafficking</td>
                <td headers="hd_h_cf.T.historical_classification_scheme_fo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Missense, splice site variants</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Based on <xref ref-type="bibr" rid="cf.REF.wilschanski.1995.705">Wilschanski et al [1995]</xref>, <xref ref-type="bibr" rid="cf.REF.zielenski.1995.777">Zielenski &#x00026; Tsui [1995]</xref> (Figure 3), <xref ref-type="bibr" rid="cf.REF.welsh.2001">Welsh et al [2001]</xref>, <xref ref-type="bibr" rid="cf.REF.cutting.2015.45">Cutting [2015]</xref></p>
            </fn>
            <fn id="cf.TF.8.1">
              <label>1. </label>
              <p>There are numerous exceptions to <italic toggle="yes">CFTR</italic> genotype-phenotype correlations (e.g., Ala455Glu is Class II but associated with mild lung disease and pancreatic sufficiency).</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <sec id="cf.Genetic_Modifiers_of_CF_Phenotype">
          <title>Genetic Modifiers of CF Phenotype</title>
          <p><bold><italic toggle="yes">CFTR</italic>, 5T/TG tract analysis.</bold> A poly T tract, a string of thymidine bases located in intron 8 of <italic toggle="yes">CFTR</italic>, can be associated with <italic toggle="yes">CFTR</italic>-related disorders depending on its size. The three common variants of the poly T tract are 5T, 7T, and 9T. Both 7T and 9T are considered polymorphic variants and 5T is considered a variably penetrant variant. The 5T variant is thought to decrease the efficiency of intron 8 splicing. Poly T testing is appropriate as a reflex test when an Arg117His variant is detected or an adult male is being evaluated for CAVD (see <xref ref-type="sec" rid="cf.Related_Genetic_Counseling_Issues">Related Genetic Counseling Issues</xref>).</p>
          <p>A TG tract lies just 5' of the poly T tract. It consists of a short string of TG repeats that commonly number 11, 12, or 13. A longer TG tract (12 or 13) in conjunction with a shorter poly T tract (5T) has the strongest adverse effect on proper intron 8 splicing [<xref ref-type="bibr" rid="cf.REF.cuppens.1998.487">Cuppens et al 1998</xref>, <xref ref-type="bibr" rid="cf.REF.groman.2004.176">Groman et al 2004</xref>, <xref ref-type="bibr" rid="cf.REF.sun.2006.339">Sun et al 2006</xref>].</p>
          <p>There are ongoing investigations of genetic modifiers of CF nutritional status, liver disease, diabetes, and lung disease. Heritability of several of these traits is high, indicating a significant role for non-<italic toggle="yes">CFTR</italic> genetic modifiers [<xref ref-type="bibr" rid="cf.REF.knowles.2012.a009548">Knowles &#x00026; Drumm 2012</xref>]. To date, the association of several genes has been replicated in multiple studies:</p>
          <list list-type="bullet">
            <list-item>
              <p><italic toggle="yes">MBL2</italic>, <italic toggle="yes">EDNRA</italic>, and <italic toggle="yes">TGF-&#x003b2;1</italic> in lung function</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">MBL2</italic> in age at first <italic toggle="yes">P. aeruginosa</italic> infection</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">MSRA</italic> in meconium ileus</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">TCF7L2</italic> in CF-related diabetes [<xref ref-type="bibr" rid="cf.REF.knowles.2012.a009548">Knowles &#x00026; Drumm 2012</xref>]</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">SERPINA1</italic> in CF-related liver disease [<xref ref-type="bibr" rid="cf.REF.bartlett.2009.1076">Bartlett et al 2009</xref>]</p>
            </list-item>
          </list>
          <p>While these genes/variants may be targeted for future therapeutic interventions, no genetic modifier is well established enough at the time of this update to offer clinical testing or change clinical management based on non-<italic toggle="yes">CFTR</italic> genotype.</p>
        </sec>
      </sec>
      <sec id="cf.References">
        <title>References</title>
        <sec id="cf.Published_GuidelinesConsensus_Stateme">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="cf.Published_GuidelinesConsensus_Stateme.reflist0">
            <ref id="cf.REF.grody.2001">
              <mixed-citation publication-type="web">Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ (Subcommittee on Cystic Fibrosis Screening, Accreditation of Genetic Services Committee, ACMG). Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/gim/journal/v3/n2/full/gim200129a.html">online</ext-link>. 2001. Accessed 1-25-17.</mixed-citation>
            </ref>
            <ref id="cf.REF.langfelderschwind.2014">
              <mixed-citation publication-type="web">Langfelder-Schwind E, Karczeski B, Strecker MN, Redman J, Sugarman EA, Zaleski C, Brown T, Keiles S, Powers A, Ghate S, Darrah R. Molecular Testing for Cystic Fibrosis Carrier Status Practice Guidelines: Recommendations of the National Society of Genetic Counselors. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://link.springer.com/article/10.1007/s10897-013-9636-9/fulltext.html">online</ext-link>. 2014. Accessed 1-25-17.</mixed-citation>
            </ref>
            <ref id="cf.REF3">
              <mixed-citation publication-type="web">National Institutes of Health. Consensus statement on genetic testing for cystic fibrosis. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://consensus.nih.gov/1997/1997GeneticTestCysticFibrosis106html.htm">online</ext-link>. 1997. Accessed 1-24-17</mixed-citation>
            </ref>
            <ref id="cf.REF.wilson.2002.644">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desilets</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reid</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaw</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Summers</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wyatt</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crane</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Armson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de la Ronde</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farine</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leduc</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Aerde</surname>
                    <given-names>J</given-names>
                  </name>
                  <collab>Society of Obstetricians and Gynaecologists of Canada</collab>
                </person-group>
                <article-title>Cystic fibrosis carrier testing in pregnancy in Canada.</article-title>
                <source>J Obstet Gynaecol Can.</source>
                <year>2002</year>
                <volume>24</volume>
                <fpage>644</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">12196844</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="cf.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="cf.Literature_Cited.reflist0">
            <ref id="cf.REF.aiken.2012.2308">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aiken</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Painter</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Chloride transport in functionally active phagosomes isolated from Human neutrophils.</article-title>
                <source>Free Radic Biol Med.</source>
                <year>2012</year>
                <volume>53</volume>
                <fpage>2308</fpage>
                <lpage>17</lpage>
                <pub-id pub-id-type="pmid">23089227</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.bartlett.2009.1076">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bartlett</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ling</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pace</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bell</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bourke</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castaldo</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castellani</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cipolli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colombo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colombo</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Debray</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacaille</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macek</surname>
                    <given-names>M</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Rowland</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salvatore</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wainwright</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilschanski</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zemkov&#x000e1;</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hannah</surname>
                    <given-names>WB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phillips</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corey</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zielenski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dorfman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zou</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silverman</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drumm</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wright</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lange</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durie</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knowles</surname>
                    <given-names>MR</given-names>
                  </name>
                  <etal/>
                </person-group>
                <article-title>Genetic modifiers of liver disease in cystic fibrosis.</article-title>
                <source>JAMA</source>
                <year>2009</year>
                <volume>302</volume>
                <fpage>1076</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">19738092</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.berwouts.2011.1197">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Berwouts</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morris</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girodon</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stuhrmann</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dequeker</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Mutation nomenclature in practice: findings and recommendations from the cystic fibrosis external quality assessment scheme.</article-title>
                <source>Hum Mutat.</source>
                <year>2011</year>
                <volume>32</volume>
                <fpage>1197</fpage>
                <lpage>203</lpage>
                <pub-id pub-id-type="pmid">21796730</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.bilton.2011.1071">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bilton</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallagher</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kolbe</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fox</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaques</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charlton</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study.</article-title>
                <source>Eur Respir J.</source>
                <year>2011</year>
                <volume>38</volume>
                <fpage>1071</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">21478216</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.bombieri.2011.s86">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bombieri</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Claustres</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Boeck</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Derichs</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dodge</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girodon</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sermet</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tzetis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilschanski</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bareil</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bilton</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castellani</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cuppens</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutting</surname>
                    <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drev&#x000ed;nek</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farrell</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elborn</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jarvi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kerem</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kerem</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knowles</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macek</surname>
                    <given-names>M</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Munck</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Radojkovic</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sheppard</surname>
                    <given-names>DN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Southern</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stuhrmann</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tullis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zielenski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pignatti</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferec</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Recommendations for the classification of diseases as CFTR-related disorders.</article-title>
                <source>J Cyst Fibros.</source>
                <year>2011</year>
                <volume>10</volume>
                <supplement>Suppl 2</supplement>
                <fpage>S86</fpage>
                <lpage>102</lpage>
                <pub-id pub-id-type="pmid">21658649</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.borowitz.2009.s106">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Borowitz</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parad</surname>
                    <given-names>RB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharp</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabadosa</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rock</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farrell</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sontag</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenfeld</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marshall</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Accurso</surname>
                    <given-names>FJ</given-names>
                  </name>
                </person-group>
                <article-title>Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond.</article-title>
                <source>J Pediatr.</source>
                <year>2009</year>
                <volume>155</volume>
                <fpage>S106</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">19914443</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.bosco.1999.1020">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bosco</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Norton</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lieberman</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Predicting the risk of cystic fibrosis with echogenic fetal bowel and one cystic fibrosis mutation.</article-title>
                <source>Obstet Gynecol.</source>
                <year>1999</year>
                <volume>94</volume>
                <fpage>1020</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">10576193</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.brigman.2006.484">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brigman</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feranchak</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Liver involvement in cystic fibrosis.</article-title>
                <source>Curr Treat Options Gastroenterol.</source>
                <year>2006</year>
                <volume>9</volume>
                <fpage>484</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">17081482</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.brock.1998.47">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brock</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gilfillan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holloway</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>The incidence of cystic fibrosis in Scotland calculated from heterozygote frequencies.</article-title>
                <source>Clin Genet.</source>
                <year>1998</year>
                <volume>53</volume>
                <fpage>47</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9550361</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.patient_registry.2011">
              <mixed-citation publication-type="web">CFF Patient Registry. Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cysticfibrosisdata.org/LiteratureRetrieve.aspx?ID=132652">online</ext-link>. 2011. Accessed 1-24-17.</mixed-citation>
            </ref>
            <ref id="cf.REF.patient_registry.2013">
              <mixed-citation publication-type="web">CFF Patient Registry. Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cff.org/2013_CFF_Patient_Registry_Annual_Data_Report.pdf">online</ext-link>. 2013. Accessed 1-24-17.</mixed-citation>
            </ref>
            <ref id="cf.REF.cheng.2012.cd000222">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cheng</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashby</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smyth</surname>
                    <given-names>RL</given-names>
                  </name>
                </person-group>
                <article-title>Ursodeoxycholic acid for cystic fibrosis-related liver disease.</article-title>
                <source>Cochrane Database Syst Rev.</source>
                <year>2012</year>
                <volume>10</volume>
                <fpage>CD000222</fpage>
                <pub-id pub-id-type="pmid">23076885</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.chmiel.1999.823">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chmiel</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drumm</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konstan</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferkol</surname>
                    <given-names>TW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kercsmar</surname>
                    <given-names>CM</given-names>
                  </name>
                </person-group>
                <article-title>Pitfall in the use of genotype analysis as the sole diagnostic criterion for cystic fibrosis.</article-title>
                <source>Pediatrics.</source>
                <year>1999</year>
                <volume>103</volume>
                <fpage>823</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10103316</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.cuppens.1998.487">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cuppens</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaspers</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costes</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teng</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vankeerberghen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jorissen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Droogmans</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reynaert</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goossens</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nilius</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cassiman</surname>
                    <given-names>JJ</given-names>
                  </name>
                </person-group>
                <article-title>Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation.</article-title>
                <source>J Clin Invest.</source>
                <year>1998</year>
                <volume>101</volume>
                <fpage>487</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">9435322</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.cutting.2015.45">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cutting</surname>
                    <given-names>GR</given-names>
                  </name>
                </person-group>
                <article-title>Cystic fibrosis genetics: from molecular understanding to clinical application.</article-title>
                <source>Nat Rev Genet.</source>
                <year>2015</year>
                <volume>16</volume>
                <fpage>45</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">25404111</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.de_boeck.2005.e463">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Boeck</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weren</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Proesmans</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kerem</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype.</article-title>
                <source>Pediatrics.</source>
                <year>2005</year>
                <volume>115</volume>
                <fpage>e463</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15772171</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.de_braekeleer.1997.208">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Braekeleer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allard</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leblanc</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simard</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aubin</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Genotype-phenotype correlation in cystic fibrosis patients compound heterozygous for the A455E mutation.</article-title>
                <source>Hum Genet.</source>
                <year>1997</year>
                <volume>101</volume>
                <fpage>208</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">9402971</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.debray.2011.s29">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Debray</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houwen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strandvik</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colombo</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease.</article-title>
                <source>J Cyst Fibros.</source>
                <year>2011</year>
                <volume>10</volume>
                <supplement>Suppl 2</supplement>
                <fpage>S29</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">21658639</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.desmond.2007.1402">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Desmond</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bailey</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>SK</given-names>
                  </name>
                </person-group>
                <article-title>The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.</article-title>
                <source>Liver Int.</source>
                <year>2007</year>
                <volume>27</volume>
                <fpage>1402</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">18036103</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.d_rk.1997.365">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>D&#x000f6;rk</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dworniczak</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aulehla-Scholz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wieczorek</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000f6;hm</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayerova</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seydewitz</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nieschlag</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meschede</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horst</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pander</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sperling</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ratjen</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Passarge</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidtke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stuhrmann</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens.</article-title>
                <source>Hum Genet.</source>
                <year>1997</year>
                <volume>100</volume>
                <fpage>365</fpage>
                <lpage>77</lpage>
                <pub-id pub-id-type="pmid">9272157</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.feldshtein.2010.713">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Feldshtein</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elkrinawi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yerushalmi</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marcus</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vullo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ofir</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landau</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sivan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Supuran</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birk</surname>
                    <given-names>OS</given-names>
                  </name>
                </person-group>
                <article-title>Hyperchlorhidrosis caused by homozygous mutation in CA12, encoding carbonic anhydrase XII.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2010</year>
                <volume>87</volume>
                <fpage>713</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">21035102</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.ferec.2012.a009480">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferec</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutting</surname>
                    <given-names>GR</given-names>
                  </name>
                </person-group>
                <article-title>Assessing the Disease-Liability of Mutations in CFTR.</article-title>
                <source>Cold Spring Harb Perspect Med.</source>
                <year>2012</year>
                <volume>2</volume>
                <fpage>a009480</fpage>
                <pub-id pub-id-type="pmid">23209179</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.friedman.1995.1353">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teichtahl</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Kretser</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Temple-Smith</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Southwick</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silverman</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Highsmith</surname>
                    <given-names>WE</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Boucher</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knowles</surname>
                    <given-names>MR</given-names>
                  </name>
                </person-group>
                <article-title>Screening Young syndrome patients for CFTR mutations.</article-title>
                <source>Am J Respir Crit Care Med.</source>
                <year>1995</year>
                <volume>152</volume>
                <fpage>1353</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">7551394</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.gilljam.2004.174">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gilljam</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moltyaner</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Downey</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devlin</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durie</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cantin</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zielenski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tullis</surname>
                    <given-names>DE</given-names>
                  </name>
                </person-group>
                <article-title>Airway inflammation and infection in congenital bilateral absence of the vas deferens.</article-title>
                <source>Am J Respir Crit Care Med.</source>
                <year>2004</year>
                <volume>169</volume>
                <fpage>174</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14551163</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.goss.2003.1460">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goss</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubenfeld</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aitken</surname>
                    <given-names>ML</given-names>
                  </name>
                </person-group>
                <article-title>The effect of pregnancy on survival in women with cystic fibrosis.</article-title>
                <source>Chest.</source>
                <year>2003</year>
                <volume>124</volume>
                <fpage>1460</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">14555580</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.grody.2001.149">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Grody</surname>
                    <given-names>WW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutting</surname>
                    <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klinger</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richards</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watson</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <etal/>
                </person-group>
                <article-title>Laboratory standards and guidelines for population-based cystic fibrosis carrier screening.</article-title>
                <source>Genet Med.</source>
                <year>2001</year>
                <volume>3</volume>
                <fpage>149</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">11280952</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.groman.2004.176">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Groman</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hefferon</surname>
                    <given-names>TW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casals</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bassas</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estivill</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Des Georges</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guittard</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koudova</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fallin</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nemeth</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fekete</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kadasi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bombieri</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pignatti</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanavakis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tzetis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Novelli</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Apice</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sobczynska-Tomaszewska</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bal</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stuhrmann</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macek</surname>
                    <given-names>M</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Claustres</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutting</surname>
                    <given-names>GR</given-names>
                  </name>
                </person-group>
                <article-title>Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2004</year>
                <volume>74</volume>
                <fpage>176</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14685937</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.hamosh.1998.255">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hamosh</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>FitzSimmons</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macek</surname>
                    <given-names>M</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Knowles</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenstein</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutting</surname>
                    <given-names>GR</given-names>
                  </name>
                </person-group>
                <article-title>Comparison of the clinical manifestations of cystic fibrosis in black and white patients.</article-title>
                <source>J Pediatr.</source>
                <year>1998</year>
                <volume>132</volume>
                <fpage>255</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9506637</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.hodge.1999.329">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hodge</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lebo</surname>
                    <given-names>RV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yesley</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheney</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angle</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milunsky</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Calculating posterior cystic fibrosis risk with echogenic bowel and one characterized cystic fibrosis mutation: avoiding pitfalls in the risk calculations.</article-title>
                <source>Am J Med Genet.</source>
                <year>1999</year>
                <volume>82</volume>
                <fpage>329</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">10051167</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.kerem.1997.35">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kerem</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiba-Falek</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kerem</surname>
                    <given-names>E.</given-names>
                  </name>
                </person-group>
                <article-title>Cystic fibrosis in Jews: frequency and mutation distribution.</article-title>
                <source>Genet Test.</source>
                <year>1997</year>
                <volume>1</volume>
                <fpage>35</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10464623</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.kiesewetter.1993.274">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kiesewetter</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macek</surname>
                    <given-names>M</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Curristin</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chu</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shrimpton</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cashman</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsui</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mickle</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>A mutation in CFTR produces different phenotypes depending on chromosomal background.</article-title>
                <source>Nat Genet.</source>
                <year>1993</year>
                <volume>5</volume>
                <fpage>274</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">7506096</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.knowles.2012.a009548">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Knowles</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drumm</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>The influence of genetics on cystic fibrosis phenotypes.</article-title>
                <source>Cold Spring Harb Perspect Med.</source>
                <year>2012</year>
                <volume>2</volume>
                <fpage>a009548</fpage>
                <pub-id pub-id-type="pmid">23209180</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.leeuwen.2014.69">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leeuwen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fitzgerald</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaskin</surname>
                    <given-names>KJ</given-names>
                  </name>
                </person-group>
                <article-title>Liver disease in cystic fibrosis.</article-title>
                <source>Paediatr Respir Rev.</source>
                <year>2014</year>
                <volume>15</volume>
                <fpage>69</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">23769887</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.mak.1999.2217">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mak</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zielenski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsui</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durie</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longley</surname>
                    <given-names>TB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jarvi</surname>
                    <given-names>KA</given-names>
                  </name>
                </person-group>
                <article-title>Proportion of cystic fibrosis gene mutations not detected by routine testing in men with obstructive azoospermia.</article-title>
                <source>JAMA</source>
                <year>1999</year>
                <volume>281</volume>
                <fpage>2217</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">10376575</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.massie.2001.1195">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Massie</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poplawski</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcken</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldblatt</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrnes</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robertson</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C.</article-title>
                <source>Eur Respir J.</source>
                <year>2001</year>
                <volume>17</volume>
                <fpage>1195</fpage>
                <lpage>200</lpage>
                <pub-id pub-id-type="pmid">11491164</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.mckone.2003.1671">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McKone</surname>
                    <given-names>EF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Emerson</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edwards</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aitken</surname>
                    <given-names>ML</given-names>
                  </name>
                </person-group>
                <article-title>Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study.</article-title>
                <source>Lancet.</source>
                <year>2003</year>
                <volume>361</volume>
                <fpage>1671</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12767731</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.moran.2010.2697">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunzell</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marshall</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Onady</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabadosa</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stecenko</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slovis</surname>
                    <given-names>B</given-names>
                  </name>
                  <etal/>
                </person-group>
                <article-title>Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society.</article-title>
                <source>Diabetes Care.</source>
                <year>2010</year>
                <volume>33</volume>
                <fpage>2697</fpage>
                <lpage>708</lpage>
                <pub-id pub-id-type="pmid">21115772</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.moran.2009.1626">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunitz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nathan</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saeed</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holme</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>W.</given-names>
                  </name>
                </person-group>
                <article-title>Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality.</article-title>
                <source>Diabetes Care.</source>
                <year>2009</year>
                <volume>32</volume>
                <fpage>1626</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">19542209</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.moran.2014.65">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pillay</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becker</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acerini</surname>
                    <given-names>CL</given-names>
                  </name>
                  <etal/>
                </person-group>
                <article-title>ISPAD Clinical Practice Consensus Guidelines 2014. Management of cystic fibrosis-related diabetes in children and adolescents.</article-title>
                <source>Pediatr Diabetes.</source>
                <year>2014</year>
                <volume>15</volume>
                <supplement>Suppl 20</supplement>
                <fpage>65</fpage>
                <lpage>76</lpage>
                <pub-id pub-id-type="pmid">25182308</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.nick.2005.513">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nick</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodman</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <article-title>Manifestations of cystic fibrosis diagnosed in adulthood.</article-title>
                <source>Curr Opin Pulm Med.</source>
                <year>2005</year>
                <volume>11</volume>
                <fpage>513</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16217177</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.noone.2000.1919">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Noone</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pue</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wakeling</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganeshananthan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simon</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silverman</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knowles</surname>
                    <given-names>MR</given-names>
                  </name>
                </person-group>
                <article-title>Lung disease associated with the IVS8 5T allele of the CFTR gene.</article-title>
                <source>Am J Respir Crit Care Med.</source>
                <year>2000</year>
                <volume>162</volume>
                <fpage>1919</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">11069835</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.oca.2009.2214">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Oca</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dreux</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000e9;rard</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simon-Bouy</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Becdeli&#x000e8;vre</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferec</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girodon</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Amniotic fluid digestive enzyme analysis is useful for identifying CFTR gene mutations of unclear significance.</article-title>
                <source>Clin Chem.</source>
                <year>2009</year>
                <volume>55</volume>
                <fpage>2214</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19833837</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.palomaki.2002.90">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Palomaki</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haddow</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bradley</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>FitzSimmons</surname>
                    <given-names>SC</given-names>
                  </name>
                </person-group>
                <article-title>Updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians.</article-title>
                <source>Genet Med.</source>
                <year>2002</year>
                <volume>4</volume>
                <fpage>90</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11882786</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.prickett.2013.255">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Prickett</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jain</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Gene therapy in cystic fibrosis.</article-title>
                <source>Transl Res.</source>
                <year>2013</year>
                <volume>161</volume>
                <fpage>255</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">23273902</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.rohlfs.2011.841">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rohlfs</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heim</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagan</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenblum</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flynn</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scholl</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akmaev</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sirko-Osadsa</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allitto</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugarman</surname>
                    <given-names>EA</given-names>
                  </name>
                </person-group>
                <article-title>Cystic fibrosis carrier testing in an ethnically diverse US population.</article-title>
                <source>Clin Chem.</source>
                <year>2011</year>
                <volume>57</volume>
                <fpage>841</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">21474639</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.rosenstein.1998.589">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rosenstein</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutting</surname>
                    <given-names>GR</given-names>
                  </name>
                </person-group>
                <article-title>The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel.</article-title>
                <source>J Pediatr.</source>
                <year>1998</year>
                <volume>132</volume>
                <fpage>589</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">9580754</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.scotet.2010.592.e1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Scotet</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dugu&#x000e9;p&#x000e9;roux</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Audr&#x000e9;zet</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Audebert-Bellanger</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blayau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>F&#x000e9;rec</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Focus on cystic fibrosis and other disorders evidenced in fetuses with sonographic finding of echogenic bowel: 16-year report from Brittany, France.</article-title>
                <source>Am J Obstet Gynecol.</source>
                <year>2010</year>
                <volume>203</volume>
                <fpage>592.e1</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">20932506</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.sheridan.2005.3493">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sheridan</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fong</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groman</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conrad</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flume</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diaz</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knowles</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutting</surname>
                    <given-names>GR</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in the beta-subunit of the epithelial Na+ channel in patients with a cystic fibrosis-like syndrome.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2005</year>
                <volume>14</volume>
                <fpage>3493</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16207733</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.sly.2013.1963">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sly</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gangell</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ware</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ranganathan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mott</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murray</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stick</surname>
                    <given-names>SM</given-names>
                  </name>
                </person-group>
                <article-title>Risk factors for bronchiectasis in children with cystic fibrosis.</article-title>
                <source>N Engl J Med.</source>
                <year>2013</year>
                <volume>368</volume>
                <fpage>1963</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">23692169</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.sosnay.2013.1160">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sosnay</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siklosi</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Goor</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaniecki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharma</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramalho</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amaral</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dorfman</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zielenski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masica</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karchin</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patrinos</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corey</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lewis</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rommens</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castellani</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penland</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutting</surname>
                    <given-names>GR</given-names>
                  </name>
                </person-group>
                <article-title>Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene.</article-title>
                <source>Nat Genet.</source>
                <year>2013</year>
                <volume>45</volume>
                <fpage>1160</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">23974870</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.sun.2006.339">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sun</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Redman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milunsky</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buller</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGinniss</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anguiano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hantash</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strom</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>CFTR 5T variant has a low penetrance in females that is partially attributable to its haplotype.</article-title>
                <source>Genet Med.</source>
                <year>2006</year>
                <volume>8</volume>
                <fpage>339</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">16778595</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.wang.2002.2066">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milunsky</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maher</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oates</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milunsky</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Analysis by mass spectrometry of 100 cystic fibrosis gene mutations in 92 patients with congenital bilateral absence of the vas deferens.</article-title>
                <source>Hum Reprod.</source>
                <year>2002</year>
                <volume>17</volume>
                <fpage>2066</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">12151438</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.watson.2004.387">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Watson</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutting</surname>
                    <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Driscoll</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klinger</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mennuti</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palomaki</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Popovich</surname>
                    <given-names>BW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pratt</surname>
                    <given-names>VM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohlfs</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strom</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richards</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Witt</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grody</surname>
                    <given-names>WW</given-names>
                  </name>
                </person-group>
                <article-title>Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel.</article-title>
                <source>Genet Med.</source>
                <year>2004</year>
                <volume>6</volume>
                <fpage>387</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">15371902</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.weiss.2005.1456">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weiss</surname>
                    <given-names>FU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simon</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bogdanova</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayerle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dworniczak</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horst</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lerch</surname>
                    <given-names>MM</given-names>
                  </name>
                </person-group>
                <article-title>Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls.</article-title>
                <source>Gut.</source>
                <year>2005</year>
                <volume>54</volume>
                <fpage>1456</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">15987793</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.welsh.2001">
              <mixed-citation publication-type="book">Welsh MJ, Ramsey BW, Accurso F, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Disease</italic>. 8 ed. New York: McGraw-Hill; 2001:5121-88.</mixed-citation>
            </ref>
            <ref id="cf.REF.wilschanski.1995.705">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wilschanski</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zielenski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Markiewicz</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsui</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corey</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levison</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durie</surname>
                    <given-names>PR</given-names>
                  </name>
                </person-group>
                <article-title>Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations.</article-title>
                <source>J Pediatr.</source>
                <year>1995</year>
                <volume>127</volume>
                <fpage>705</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">7472820</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.witt.1996.823">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Witt</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaefer</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hallam</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blumberg</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fishbach</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holtzman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kornfeld</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nemzer</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palmer</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Cystic fibrosis heterozygote screening in 5,161 pregnant women.</article-title>
                <source>Am J Hum Genet.</source>
                <year>1996</year>
                <volume>58</volume>
                <fpage>823</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">8644747</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.yu.2012.25">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ni</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>Z.</given-names>
                  </name>
                </person-group>
                <article-title>CFTR mutations in men with congenital bilateral absence of the vas deferens (CBAVD): a systemic review and meta-analysis.</article-title>
                <source>Hum Reprod.</source>
                <year>2012</year>
                <volume>27</volume>
                <fpage>25</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">22081250</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.zielenski.1995.777">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zielenski</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsui</surname>
                    <given-names>LC</given-names>
                  </name>
                </person-group>
                <article-title>Cystic fibrosis: genotypic and phenotypic variations.</article-title>
                <source>Annu Rev Genet.</source>
                <year>1995</year>
                <volume>29</volume>
                <fpage>777</fpage>
                <lpage>807</lpage>
                <pub-id pub-id-type="pmid">8825494</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="cf.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="cf.Suggested_Reading.reflist0">
            <ref id="cf.REF.moskowitz.2005.739">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moskowitz</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibson</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Effmann</surname>
                    <given-names>EL</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment.</article-title>
                <source>Pediatr Radiol</source>
                <volume>35</volume>
                <fpage>739</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">15868140</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.rubenstein.2005.385">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rubenstein</surname>
                    <given-names>RC</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Novel, mechanism-based therapies for cystic fibrosis.</article-title>
                <source>Curr Opin Pediatr</source>
                <volume>17</volume>
                <fpage>385</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">15891431</pub-id>
              </element-citation>
            </ref>
            <ref id="cf.REF.welsh">
              <mixed-citation publication-type="book">Welsh MJ, Ramsey BW, Accurso F, Cutting GR. Cystic fibrosis. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> New York: McGraw-Hill. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="cf.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="cf.Author_History">
          <title>Author History</title>
          <p>Edith Cheng, MS, MD (2001-present) James F Chmiel, MD; Case Western Reserve University School of Medicine (2008-2017) Garry R Cutting, MD (2001-present) Ronald L Gibson, MD, PhD; University of Washington (2001-2008) Barbara A. Karczeski, MS, CGC, MA (2017-present)Susan G Marshall, MD (2001-2004; 2017-present) Samuel M Moskowitz, MD; Massachusetts General Hospital (2004-2017) Thida Ong, MD (2017-present)Darci Sternen, MS, LGC (2001-present) Jonathan F Tait, MD, PhD; University of Washington (2001-2004)</p>
        </sec>
        <sec id="cf.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>2 February 2017 (sw) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>19 February 2008 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>24 August 2005 (cd) Revision: changes to ACMG-recommended mutation panel</p>
            </list-item>
            <list-item>
              <p>24 August 2004 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>26 March 2001 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>6 October 1998 (jt) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
